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Glossary of Acronyms v
ANT………………………………………………………………………Actor-Network Theory 
 Popularized by Bruno Latour, this study claims that the success or failure of a technology  
 is determined by the social context in which it is used. !
EMT…………………………………………………………….Emergency Medical Technician !
FDA……………………………………………………..[U.S.] Food and Drug Administration !
FOPH…………………………………………………..[Swiss] Federal Office of Public Health !
HAT………………………………………………………………….Heroin-Assisted Treatment 
 This harm-reduction treatment prescribes diacetylmorphine, or medical-grade heroin, to  
 people suffering from opioid addiction. It is a form of Medication-Assisted Treatment. !
IOT………………………………………..………………………..Injecting Opioid Treatment  !
LAAM………………………………………………………………Leo-Alpha Acetyl Methadol 
 This long-acting treatment for opioid addiction was eventually found to be tied to heart  
 failure and taken off the market. It is a form of Medication-Assisted Treatment. !
MAT…………………………………………………………….Medication-Assisted Treatment 
 This encompasses any treatment for drug addiction that uses drugs as one of the ways  
 in which patients are treated for their addiction. !
MMT………………………………………………………..Methadone Maintenance Therapy 
 This harm-reduction treatment maintains patients on methadone, rather than attempting  
 to reduce dosage and reach abstinence. It is a form of Medication-Assisted Treatment. !
NGO…………………………………………………………..Non-Governmental Organization !
NHS……………………………………………………………[British] National Health Service !
PROVE……………………….Projekt zur ärztlichen Verschreibung von Betäubungsmitteln 
 Roughly translated from German to “Medical Study of Prescription Narcotics,” this  
 Swiss study paved the way for Switzerland’s implementation of HAT programs. !
RIOTT………………………………………..Randomised Injectable Opioid Treatment Trial 





 My grandfather, Dr. Edward Kitfield, postpones his family practice in rural Maine every 
Wednesday so that he can run a treatment clinic for patients with opioid dependence. Marisa 
Hebble works in the Executive Office of the Trial Court in Boston to improve relationships 
between the systems of criminal justice and addiction treatment. Dr. Ruth Potee is a driving force 
behind revolutionary approaches to treating addiction in western Massachusetts. These 
individuals are important and connected in two ways: they are all actors in the movement against 
opioid addiction and overdose in the U.S., and each of them inspired me to explore potential 
improvements in America’s response to the current opioid epidemic. 
!
 At this very moment, the United States is suffering from widespread addiction. The 
situation is bleak in any country with a black market for narcotics, but the issue of opioid 
addiction and overdose is enormous in the United States: in 2016, drug overdoses killed over 
64,000 Americans, and close to 55% of those deaths were due to opioid overdose.  These 1
statistics dwarf the 6,800 opioid overdose deaths in the entire continent of Europe in 2014, 
providing a case for the fact that opioid dependence is known as the “American disease.” ,   2 3
!
 We have tried to combat the crisis as a nation, but nothing has been successful in slowing 
the spread and reducing the harm to individuals and to society. The policies that the U.S. 
 National Institute on Drug Abuse, “Overdose Death Rates,” NIDA.1
 “Preventing Overdose Deaths in Europe.” European Monitoring Center for Drugs and Drug Addiction.2
 Arnold S. Trebach, The Heroin Solution (Unlimited Publishing, 2006) xii.3
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government has implemented in various attempts to ameliorate the problem are actually 
suspected of making it worse. Intensifying incarceration without providing medication or mental 
support does little—if anything—to help former inmates fight their opioid dependence before 
being released back into society. “As congress and state legislatures enact more punitive and 
costly drug control measures, we conclude with alarm that the war on drugs now causes more 
harm than drug abuse itself.”  The war on drugs not only destroyed the lives and chances of 4
becoming sober by failing to provide treatment for convicts with addiction, it destroyed the lives 
of nonviolent citizens who were reprimanded for mere possession and the color of their skin. In 
The New Jim Crow, author Michelle Alexander notes that “convictions for drug offenses are the 
single most important cause of the explosion in incarceration rates in the United States.”  Her 5
book emphasizes the racial disparity between black and white inmates, which will be touched on 
later. 
!
 The approach of this so-called “war” is to shut down the supply of drugs rather than 
focusing on the most important question: why are so many people demanding them? “As long as 
the nation’s appetite for drugs remains strong, the traffickers are going to find a way to supply it. 
Any progress made in tackling the drug problem, then, is going to have to come at home.”  By 6
attributing American drug issues to the supply part of the equation, the U.S. is able to place 
blame on the countries that grow such drugs, avoiding the admittance of accountability and 
 James P. Gray, Why Our Drug Laws Have Failed and What We Can Do about It (Temple University 4
Press, 2012) 3.
 Michelle Alexander, The New Jim Crow (New York: The New Press, 2010 ) 59.5
 Michael Massing, The Fix (Simon & Schuster, 1998) 9.6
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ruining its relationships with countries such as Mexico, while also locking up many of its own 
citizens for their use and addictions. 
!
 This is a product of a national mindset that limits definitions of success to abstinence 
alone. Despite the work of many other developed countries to wage said war by providing 
medication, counseling, and agency together in the form of an integrated treatment program for 
those who struggle with addiction, the United States is extremely reluctant to adopt such 
strategies. Most of this reluctance stems from our refusal to change our mindset from its current 
focus of individualism. 
!
 Individualism is the shared belief that anything that happens to an individual is a result of 
their own choices; everyone is responsible for their own behaviors and future; your success is 
earned through hard work, and your failures are deserved because you did something wrong. 
Everything in the U.S. is individualized: students who drop out of school are unmotivated, 
individuals who can’t hold a job have personality problems, female-bodied people who have 
children while they’re young are slut-shamed. In a similar tone, people are dependent on drugs 
because they opted to try the substance in the first place, and they can’t complete the treatment 
programs because they aren’t trying hard enough. Even when someone who doesn’t use drugs 
themselves but spends time with someone who uses drugs contracts HIV, society remains 
unsympathetic because they chose to spend time with someone in an at-risk population. 
!
!4
 In the U.S., there is limited knowledge of and support for the approaches classified under 
“harm reduction.” Their common goal is to minimize the amount of harm done to communities, 
public health, and the at-risk individuals as well. “Drugs, the harm reductionists argue, are here 
to stay, and we have no choice but to learn how to live with them.”  Sometimes, these policies 7
challenge preconceived notions of morality and efficacy, and so the process of their 
implementation can be rigorous. This is the case in the United States. Gaining traction and the 
subsequent public approval can be difficult in the current environment, given that President 
Trump himself believes that there is no place for addiction or drug use throughout the nation. In 
March of 2018, he remarked that “addiction is not our future,” and “we will raise a drug-free 
generation of American children,” entirely discounting the significant prevalence of substance 
use and abuse in the United States, and demonstrating an extremely individualistic view of the 
way in which drugs are consumed and physiologically received.  8
!
 In other corners of the world, progress has been made towards reducing drug addiction 
and its associated harms. For example, Switzerland made the bold move of testing and 
implementing Heroin-Assisted Treatment, or HAT. The program would maintain a population 
struggling with opioid dependence on prescription heroin in order to reduce drug-related 
damages. This approach took an ancient technology, heroin, and applied it in a new, remedial 
way for patients who found no success with other treatment methods. Regarding the necessity of 
treatments that may be of a controversial nature, Dr. Potee notes that “the more tools in the 
 Massing, 10.7
 The White House, “Remarks by President Trump on Combatting the Opioid Crisis,” 2018.8
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arsenal to treat addiction, the better…no one is going to deny that.”  Unfortunately, many 9
barriers remain firm as our ‘arsenal’ retains many vacancies. 
!
 This thesis will look at the use of drugs and the reception of addiction treatments in the 
United States, Switzerland, and Britain. In it, I will claim that HAT would be a very beneficial 
weapon in the battle for appropriate responses to widespread addiction, but that the success of 
the particular treatment requires a certain amount of societal support. In the first chapter, I will 
give a brief history of opioid use, addiction, and prescription, as well as a timeline of addiction 
treatments. Then, I will frame the issue of opioid addiction in various contexts through the lens 
of Actor-Network Theory, and it is here that I will more explicitly define HAT and the role of 
heroin as a technoscience. In the third chapter, I will examine Switzerland’s unprecedented 
response to its opioid problem, and delve into the ways in which the HAT approach was 
successful in that particular context. Next, I will perform the same examination on Britain, using 
it as an intermediate example to more appropriately compare with the United States. Finally, in 
my fifth and final chapter, I will look at the implications of Europe’s HAT programs on the 
current U.S. situation and argue that HAT should be implemented but, due to the current 
socioeconomic and political tensions in the U.S., it is not feasible. To conclude, I will accuse 
HAT and other responses to addiction of taking a downstream approach that address the 
symptoms of addiction rather than the root causes, and I will provide big-picture suggestions 
based on this fundamental flaw. 
!
 Joshua Solomon, “NIH Study Validates Local Opioid Treatment Plan as a Nationwide Model,” The 9
Recorder.
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 Before embarking on this transcontinental journey, I need to define some terms that will 
be used throughout the rest of the piece. I will use the term “opioid” addiction to describe 
addiction to any naturally-occurring drug derived from the poppy plant, as well as semi-synthetic 
and synthetic drugs, such as oxycodone and fentanyl, that bind to the same receptors and mimic 
the effects of the natural derivatives, which include morphine and codeine.  Typically, the 10
natural substances are referred to as opiates and the (semi-) synthetic substances are considered 
opioids, but I will lump them all into the latter term. This is an attempt to emphasize the role of 
prescription drugs and the medical industry in widespread addiction while also recognizing that 
some addictions begin, endure, and end with heroin and aren’t initiated or influenced by a legal 
prescription. I will use the term “epidemic” because that is how widespread, increasingly dense 
addiction is recognized on a national level, but I mean it in a less formal, technical sense. I will 
not use the word “addict” to mean someone who is struggling from opioid dependence, because 
that rhetoric defines them by their addiction alone and can be detrimental to recovery and 
sustained mental health. Instead, I will describe individuals as “people with opioid dependence,” 
for that more appropriately describes their physical situation rather than limiting them to 
stereotypically associated behaviors.  
!
 To find a solution to any problem, you must understand the problem itself. This particular 
problem can be defined in a number of ways, depending on the scope and perspective. On a large 
scale, addiction is the problem and opioid addiction happens to be its most severe manifestation. 
Opioid addiction involves many variables, including the quality of black market drugs, safety 
 Stephanie Labonville, “Opiate, Opioid, Narcotic - What's the Difference?” IWP.10
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and sanitation during consumption, drug-related crime as necessary to sustain use, and the 
potential for unknowingly buying pills that are laced with more lethal substances. The solution to 
this problem is complex. We can try to put bandaids on the collateral consequences via 
incarceration and prohibition but the real solution lies at the root of the problem, which has yet to 
be concretely determined. While we search for long-term solutions, we need to keep doing work 
because lives are being lost. Standard medical practices for other illnesses turn to treatment when 
a cure has yet to be discovered. So, let’s address the symptoms of this destructive disease. 
Europe has already begun to do so, and it has seen great success.  
!8
Chapter 1 - History of the Treatment of Opioid Dependence 
!
 It is widely believed that this opioid epidemic, as it has been controversially labeled, 
began when American physicians became lenient with the prescription of opioids, known for 
being highly addictive. A wave of overprescription was pushed by a societal drive for better pain 
management, for previous decades had seen a cruel refusal to prescribe to anyone other than 
cancer patients or those with no more than a few weeks of life remaining.  Once the target 11
audience had expanded, overprescription became the norm. The prescription of opioids increased 
by a factor of four between 1999 and 2010, an increase that was mirrored in the drastic spike in 
opioid overdose deaths.  When the crisis was illuminated, the U.S. witnessed an abrupt 12
cessation in prescriptions. Despite the resulting drop in prescription quantities and frequencies, 
the amount of opioids prescribed in 2015 was still three times as high as that of 1999.  Not only 13
did the crackdown on physicians barely reduce addictions and deaths, the sudden change left 
many patients severely addicted. This, in combination with price increases, drove those 
struggling with addiction to the black market in search of heroin to satisfy their cravings.  14
!
 Additionally, it is no small secret that the influence of drug companies on American 
prescription and consumption is strong. Advertisements for opioids were often misleading and 
 Barry Meier, perf. “Chasing Heroin,” PBS Frontline, 2016.11
 Jerry P. Guy Jr. et al., “Vital Signs: Changes in Opioid Prescribing in the United States, 2006 - 2015,”  12
CDC, 697.
 Ibid.13
 Jessica Ravitz & Gena Somra, “What two current heroin addicts want you to know,” CNN, 2017.14
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underemphasized the strength and addictive power of the drugs. One of the most controversial 
marketing campaigns was that in which Purdue Pharma insisted that patients had a reduced risk 
of abuse and addiction when taking Oxycontin, its pride and joy, than other painkillers.  This 15
proved to be fatally untrue. Now, after a plethora of lawsuits and much public frustration, it is 
generally understood that “Purdue is the central actor who orchestrated the opioid crisis, now 
causing hundreds of thousands of overdose deaths per year. It controls the manufacturing, 
distribution, and marketing of lethal drugs.”  16
!
 Though there exist various hypotheses as to why heroin addiction exists and spreads as it 
does in the U.S., some experts don’t believe that the problem is entirely fixable. “There is no 
pharmacological explanation of why some people get addicted and others do not.”  However, 17
pharmacology is just one aspect of addiction. On a segment for WGBY, Marisa Hebble and Dr. 
Potee discuss the underlying factors of addiction. Potee mentions that “genetics is huge. And 
telling your kids about what your family’s genetic risk is is critical…your kids would know if 
there were strong cancer genes in your family...50% of all addiction is genetic.”  Both women 18
then agree that childhood trauma is another suspect, for “there’s no better way to sort of numb up 
psychologic pain than alcohol or opiates.”   19
 Barry Meier, “In Guilty Plea, OxyContin Maker to Pay $600 Million,” The New York Times.15
 Ryan Hampton, “Purdue Pharma: You Can't Wash Away Your Part In The Opioid Crisis,” The 16
Huffington Post.
 Trebach, 69.17
 Ruth Potee, perf. “Franklin County Opioid Treatment Center,” WGBY [Springfield, MA], 2016.18




 Social and genetic factors contribute largely, and there are plenty of theories about initial 
heroin use that would dictate whether or not a certain individual takes the leap in the first place. 
But even once we’ve found a response that reduces the number of lives lost and addiction-
associated health and social problems, the needs of the community will continue to change as the 
community itself shifts from one situation to another. “The balance [between complete 
repression and allowance of heroin] cannot be achieved in a mechanistic manner, like building a 
bridge, or in a purely scientific fashion, like creating a new drug. It can be pursued only by using 
human relations skills in combination with a knowledge of history, medicine, and law.”  This 20
epidemic is dynamic, so the societal responses must be as well. As our current paradigm of 
individual achievement and failure shifts and what we know is challenged, we must reorganize 
and be creative in responding to the issues that plague the nation. 
!
A. Timeline of Treatments 
 For decades, he United States has recognized that a remedy lies in the field of medicine. 
As an alternative to incarceration in 1960s New York City, people who were dependent on drugs 
could voluntarily be committed to facilities following a medical exam to confirm the existence of 
an addiction.  The incorporation of the medical exam indicates that the medical community had 21
acknowledged the underlying biology of addiction. Unfortunately, these programs were 
 Trebach, ix.20
 Center for Substance Abuse Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid 21
Treatment Programs, Treatment Improvement Protocol (TIP) Series 43, 2005, 15.
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minimally successful and extremely expensive.  “The great majority of those admitted, treated, 22
and paroled to aftercare programs dropped out of these programs, and they usually could not be 
located.”  Perhaps the low retention rates were a result of the programs’ heavy connection to 23
law enforcement and government coercion, themes not often appreciated by those who are 
already criminalized for their struggle with addiction.  Further, “even though they were civil 
commitments, the fact of the matter was that most were there under some sort of legal 
pressure.”  This is subjectively unethical, since it can be seen as a form of government coercion 24
in which citizens are forced to take drugs. 
!
 Twice, first in 1955 and again in 1963, the New York Academy of Medicine 
recommended the establishment of clinics that would dispense opioids in a controlled manner to 
those who were addicted to illicit heroin.  They began with morphine, which wasn’t ideal. The 25
chemical had a short half-life, so associated programs required multiple injections per day, and it 
sedated patients as well.  Both setbacks prevented patients from carrying on with their daily 26
routines, driving researchers to continue the pursuit of a reasonable treatment.  
!
 Richard C. Stephens, The Street Addict Role: a Theory of Heroin Addiction (New York: State 22
University Press, 1991) 167.
 Center for Substance Abuse Treatment, 15.23
 Stephens, 167.24
 Center for Substance Abuse Treatment, 16.25
 Ibid., 17.26
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 In the late 1960s, Leo-Alpha Acetyl Methadol (LAAM) was discovered and suppressed 
withdrawal symptoms for two to three days.  This long-acting drug was praised for its ability to 27
let patients go on with their normal employment and familial routines. But all good things must 
come to an end: much to the medical world’s disappointment, LAAM was eventually linked to 
cardiac issues and pulled from the market, leaving methadone as the top choice for treatment of 
opioid dependence.  
!
 Methadone, a long-acting, synthetic opioid, was extremely effective where other 
treatments had failed. But it still required a dose a day—better than morphine, but less than ideal 
for those with families and jobs. The long-acting nature of methadone makes it much more 
appealing to physicians and the public than heroin itself, especially since it provides none of the 
euphoria and doesn’t require take-away doses, which can leak to the black market. Additionally, 
“Methadone has few adverse biological effects.”  However, methadone is still highly addictive 28
and is associated with an extremely painful withdrawal period, making the process of decreasing 
doses tedious and difficult. Despite such limitations, Methadone, with its established presence in 
the U.S. and its use as a maintenance drug, will come in handy later as a prototype for 
Medication-Assisted Treatment (MAT) with which to contrast HAT. 
!
 Similar to the obstacles challenging HAT today, Methadone and Methadone Maintenance 
Therapy (MMT) faced a significant amount of national scrutiny when they were first introduced 
 Center for Substance Abuse Treatment, 18.27
 NIDA International Program, Methadone Research Web Guide, Part B-44.28
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as treatment options for opioid-dependent patients. The intensity of the country’s drug addiction 
problem was such that President Nixon called it “public enemy number one.”  The epidemic, as 29
it was also called back in 1971, drove policy change as it has the potential to do again. “President 
Nixon shifted federal government policy on opiate addiction away from its strictly punitive 
philosophy,” and succeeded in implementing methadone programs.  This was all well and good, 30
but despite Nixon’s role as a powerful player, it wasn’t easily accepted by the general public. 
“The pioneer methadone-dispensing physicians, as might be expected, faced some community 
opposition; they were, after all, dispensing an addicting drug to addicts.”  Due to criticisms that 31
arose in 1973 and are still embedded in anti-MAT ideologies today that rely on the idea that MAT 
merely replaces one addictive drug with another, the government imposed strict regulations on 
the prescription and the use of methadone.  32
  
 In the United States, Methadone was regulated by the FDA until 2001.  This was 33
somewhat limiting, as they had strict rules regarding levels of addictiveness, so the medication 
was rarely encouraged or permitted. In 2001, physicians complained, feeling that, as trained 
medical professionals, they knew whether or not it was appropriate to prescribe methadone based 
on the circumstances. “The new regulations acknowledged that addiction is a medical disorder 
not amenable to one-size-fits-all treatment. They recognized that different patients, at different 
 “Soldiers, Hippies and Richard Nixon—an American History of Methadone,” CRC Health Group.29
 CRC Health Group.30
 Edward M. Brecher, Licit and Illicit Drugs (Little, Brown, 1988), 18.31
 CRC Health Group.32
 Brecher, 22.33
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times, could need vastly different services.”  This led to the development of maintenance 34
programs, a strategy that demonstrates movement towards a more progressive understanding of 
addiction and its potential remedies. However supportive and relatively in line with harm 
reductionist approaches, the treatment doesn’t come without inadequacies and flaws.  
!
B. Maintenance Therapy vs. Abstinence-Based Treatment 
 Abstinence has been the primary goal of anti-addiction responses in the U.S. for as long 
as drug use has been recognized as an issue. Despite its prominence, and like any treatment for a 
physical disease, there are many limitations. Some programs involve counseling, community-
building, and other drugless methods. The 12-step model proposed by Alcoholics Anonymous 
(and used for other forms of substance dependence) supports the notion that “people can help 
one another achieve and maintain abstinence from the substances or behaviors to which they are 
addicted.”  Others use drugs, but always with the intention—and strict requirement—of 35
complete reduction.  
!
 The fundamental goal of MAT—treating opioid addiction with more drugs, often opioids 
themselves—is to gradually decrease dosage until the individual is successfully weaned off of 
their drug of choice. This works well for some people. Others can retain sobriety for a while but 
will eventually relapse, and there are others still who won’t be able to make it to the end of the 
program before engaging in illicit drug use again.  
 Center for Substance Abuse Treatment, 22.34
 “12 Step Programs for Drug Rehab & Alcohol Treatment,” American Addiction Centers, 2018.35
!15
 A controversial option for those patients is the notion of maintenance as opposed to the 
abstinence-based treatment known as detoxification. Dr. Potee dislikes the notion of 
detoxification programs. She argues that addiction “is a disease…if I told everybody you need to 
detox off of your diabetes meds in five days, that’s impossible.”  Maintenance programs are 36
analogous to long-term, continuous treatment programs for any disease, and provide a natural 
remedy to suppress harmful symptoms. If addiction were to be fully understood in this way, there 
would be no question about whether or not those with opioid dependence deserve to be treated 
with whatever it takes, including maintenance programs.  
  
 In the late 1960s, Dole & Nyswander posited that, in their years of using heroin, addicts 
“underwent a permanent metabolic change. They needed narcotics in a visceral way, the way a 
diabetic needed insulin. This would explain relapse, and why complete abstinence was not an 
attainable goal for the majority of narcotic addicts.”  Thus, the movement for drug maintenance 37
treatment was born, despite the national opposition to anything but abstinence. 
!
 Ideally, patients will become stable and be able to decrease dosage down to nothing, but 
proponents of maintenance programs acknowledge that long-term stabilization is practical as 
well. Maintenance programs are in place to encourage and support patients, for dosages aren’t 
required to decrease and, in some cases, patients are able to choose their own doses. A 
maintenance treatment “recognizes that drugs will always be with us and that there will always 
 WGBY[Springfield, MA].36
 David T. Courtwright, “The Prepared Mind: Marie Nyswander, Methadone Maintenance, and the 37
Metabolic Theory of Addiction,” Addiction, 259.
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be some demand for them. So it provides full and accurate information and prepares as many 
people as possible to make responsible choices about their use.”  Because of this and the 38
positive socioeconomic effects of maintenance programs, they are classified under the harm 
reduction umbrella.  
!
 MMT is arguably the most well-known type of maintenance program, at least in the 
United States. “Cushman and Dole (1973) cautiously note that the subjects who were successful 
were highly motivated, had stable families and jobs, and were far from representative of the 
population in treatment.”  MMT doesn’t work for all people who struggle with addiction; in 39
fact, the populations for which it fails are typically those who are most likely to become addicted 
in the first place. “Overall, the risk of failure was greater for those who were unemployed or 
unmarried, confirming their earlier work (Perkins and Bloch, 1970), which suggested that 
unemployment was associated with continued drug abuse.”  Unemployment is one of the 40
societal causes, implying that with MMT as the only treatment option, those who are 
unemployed are very unlikely to break the cycle of addiction. 
!
 MMT doesn’t work for everyone, and allows a lot of people with less motivation and 
fewer societal advantages to fall through the cracks. MAT in general could be improved by more 
psychosocial assistance such as contingency management, which provides goals and incentives 
 Gray, 178.38
 Jerome J. Platt and Christina Labate, Heroin Addiction: Theory, Research, and Treatment (R.E. Krieger 39
Pub. Co., 1986) 287.
 Platt & Labate, 283.40
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for abstinence, and has been shown to improve clinic attendance, and would likely help those 
most at risk for relapse to remain in their treatment program.  But not everyone is willing to 41
engage in drug treatment of any kind. Many drug users "don't trust the health care system: if they 
got addicted to drugs because a doctor prescribed them opioid painkillers, they have a good 
reason to distrust doctors who are now trying to get them to take another medication--this time 
for their addiction."  42
!
 Out of those who do participate, not everyone is successful when treated with decreasing 
dosages. For many, maintenance programs are more reliable because they don’t require a 
reduction in dosage, which can drive many to seek illicit drugs to supplement the inadequate 
dosage prescribed. Some countries have experimented with maintenance programs because they 
consider a safe, healthy addiction a step in the right direction. Though not as ideal as total 
abstinence, it’s more realistic, and doing something to minimize harm is a great success.  
!
 President Trump’s former Health and Human Service Secretary, Dr. Tom Price, criticized 
MAT, arguing that “if we’re just substituting one opioid for another, we’re not moving the dial 
much.”  The U.S. legally allows MAT, but its skepticism is likely discouraging to physicians, 43
unwelcoming to patients, and influential to uninformed citizens who might develop an anti-MAT 
mindset. Further, the country is less supportive of maintenance programs such as MMT due to 
 Peter Blanken et al., “Outcome of Long-Term Heroin-Assisted Treatment Offered to Chronic, 41
Treatment-Resistant Heroin Addicts in the Netherlands,” Addiction, 141.
 German Lopez, "There's a highly successful treatment for opioid addiction. But stigma is holding it 42
back," Vox.
 Eric Eyre, “Trump Officials Seek Opioid Solutions in WV,” Charleston Gazette-Mail.43
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the lack of emphasis on total abstinence. Methadone detoxification is more widely used and 
supported than methadone maintenance, and though it helps to reduce the symptoms of opioid 
withdrawal, it isn’t effective when it comes to opioid dependence.  If the government were to 44
support MMT more, questions of coercion and political ethics would plague the newfound 
funding. “Government support of methadone programs has often resulted in questionable 
practices such as requiring participation in a methadone program as a condition of parole.”  45
Again, this could be interpreted as the government forcing patients to consume drugs and 
punishing them if they don’t.  
!
 If the government-supported drug were heroin, would the ethics be less murky? After all, 
the user may have already chosen to take that exact drug, so it may be less of an issue whereas 
methadone is unfamiliar to those who have exclusively used heroin prior to government 
intervention. Additionally, people with dependencies tend to prefer the euphoria and familiarity 
of heroin that aren’t experienced with methadone, so they’d likely be more willing to participate 
in maintenance programs if heroin were the drug being maintained. Further, Richard Stephens 
points out that people with drug dependence often exist in isolated subcultures that have rejected 
societal norms and created their own definitions of success and status. These “subcultural aspects 
of addiction” are such that people with opioid dependence seek to gain social status through the 
use of drugs, perhaps counterintuitively, and thus might want to continue using the drug with a 
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Minimal Counseling versus 21-Day Methadone Detoxification,” Drug and Alcohol Dependence, 2.
 Platt & Labate, 288.45
!19
rebellious reputation as opposed to one enforced by the government.  However, as one could 46
imagine, the idea of using heroin as a supplementary treatment for opioid addiction would face 
much criticism from the U.S. government and the American public.  
 Stephens, xi.46
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Chapter 2 - Actor-Network Theory and HAT 
! !
Even if few people still believe in the naïve view, courageously defended by epistemologists, that 
sets science apart from noise and disorder, others would still like to provide a rational version of 
scientific strategy, to offer clear-cut explanations of how it develops and why it works. They would 
like to attribute definite interests to the social groups that shape science, to endow them with 
explicit boundaries, and to reconstruct a strict chain of command going from macrostructures to the 
fine grain of science. Even if we have to give up our beliefs in science, some of us still wish to 
retain the hope that another science, that of society and history, might explain science.  !
Bruno Latour, The Pasteurization of France, p. 6 !
 Science is typically thought to be synonymous with institutional order, normative 
structure, and a dichotomous comparison of truth and falsity. It isn’t often that science is 
attributed to “social groups” or “society and history.” Bruno Latour, in writing about 
technoscience and contextual actor-networks, challenged the common understanding of the 
practice and presentation of science, hurling all of society’s communities into an unfamiliar 
paradigm of interconnectivity, and distinguishing his own thoughts on the relationships between 
science, technology, and society from those of scientific sociologists who had previously claimed 
that each aspect—the noise of social interaction and the purity of scientific exploration—could 
be isolated and independently examined in full. 
!
 “Technoscience” refers to the idea that technology and the science from which it stems 
cannot be separated. You can’t begin to examine a technology without understanding its source 
and its scientific products. Further, it is impossible to remove science or technology from its 
social context; the technoscience that surrounds us is dependent on society, and its efficacy is 
determined by whether or not we can finagle a system of social interrelations that will support it. 
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 This system of social interrelations can be visualized as a web composed of entities and 
connective lines, marking their relationships to one another. Actor-Network Theory, or ANT, is 
the framework that considers both human actors and non-human actants, and explores their 
relationships within this social web. Each society, community, and social situation can be 
represented as such a network of actors and actants, some with abundant connections and some 
with very few. “A network metaphor is thus a way of underlining the simultaneously social and 
technical character of technological innovation. It is a metaphor for the interconnected 
heterogeneity that underlies sociotechnical engineering.”  47
!
 This construction of the actor-network relies on a few complex notions, that will be 
perhaps oversimplified for the purposes of this thesis. Enrollment is a term used to describe the 
definition and distribution of roles to the actors and actants in the actor-network, imposed—
sometimes unsuccessfully—by the situation around which the network forms.  Translation, or 48
the method by which various actors are enrolled in the network, makes connections between two 
entities and allows for communication both ways.   49
!
 The role of a network in producing and sustaining technoscience is one of context. When 
a technology or scientific observation is first introduced, the outcome depends on the network 
that forms around it. “We should not ask if this network is more powerful than another; rather, 
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we should ask if this association is stronger than another one. Any actor-network, then, is the 
effect, or result, of the connections that constitute it.”  A network’s support is, in turn, 50
determined by the strength and nature of the relationships between actors and actants: does one 
influence the other? is it a positive, mutual translation, or is there tension between the two? are 
the nodes communicating effectively? We ask such questions in an attempt to explore the 
network and seek out the source(s) of a technoscience’s success or failure.  
!
 Latour himself notes that “our entry into science and technology will be through the back 
door of science in the making, not through the more grandiose entrance of ready made 
science.”  The study of this science in the making examines the places where science and 51
technology originate, including physical structures such as labs and boardrooms, as well as 
congregations: institutes, government departments, and funding agencies.  ANT can be used as a 52
framework with which to follow the paths within the network, striving to identify the various 
roles and relations of actors in an attempt to unpack technoscience.  
  
 To illustrate the construction of a network and each of its contributing actors, we will use 
HAT as an example. HAT, as a medical response to opioid addiction, has been successfully 
incorporated into some networks and rejected by others. It is a form of technoscience that has the 
potential to help and to harm, depending on the actors involved. Though the entire notion of 
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technoscience is founded on the integration of science, technology, and social tensions, each 
component can be simplified for the sake of identifying the key points of understanding 
necessary for the rest of this thesis. 
!
A. Heroin as Chemical Technology 
 In 1976, Platt and Labate wrote about the emergence of HAT, also known as Heroin 
Maintenance, from failures of current U.S. policy and other medications aimed to wean patients 
off of illicit drugs. “Increasingly, the issue is being raised that perhaps heroin should be provided 
in some controlled legitimate fashion to addicts until an effective cure is discovered. There is 
little disagreement that the current treatment effort is inadequate and ineffective.”  Since then, 53
not much has changed. Only about 10% of Americans dependent on opioids are receiving 
treatment.  54
!
 HAT, though illegal and unpracticed in the United States, has been experimented with in 
a number of other countries, primarily those in Western Europe. Programs look similar to MMT, 
but with the substitution of heroin for methadone. The programs are specifically for those who 
have shown resistance to MMT programs and have yet to find stabilizing success elsewhere. 
Though heroin maintenance “can act as a bridge to ultimate abstinence or, at least, reduced use. 
It does not demand total and immediate abstinence,” it is perhaps the most controversial harm-
reduction method known to addiction experts, as it goes beyond the decriminalization of illicit 
 Platt & Labate, 247.53
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heroin—already very unlikely in today’s political climate—to encourage the prescription of the 
drug as a medical remedy for addiction.  55
!
 The general composition of a HAT program includes the prescription of diamorphine—or 
diacetylmorphine: medical-grade, pure, uncut heroin. This is provided so as to ensure that 
patients’ drugs aren’t cut with more potent, lethal substances, and to direct traffic away from the 
black market and towards monitored clinics. In congruence with the prescription medication, the 
administration setting is tailored to fit the needs of patients and reduce harm as much as possible. 
This usually consists of a number of supportive provisions: trained nurses or volunteers on-site 
with accessible Naloxone to administer in the event of an overdose, clean needles and cookers so 
as to minimize the spread of disease, sterile indoor facilities to maintain hygiene and warmth.  
  
 Why does it matter which opioid is prescribed, if they have similar chemical 
compositions, addictive potentials, and withdrawal symptoms, and each one benefits a certain 
population? “[Casriel and Bratter, 1974] raise an interesting point in noting the illogic of making 
one narcotic legal and another illegal. ‘Is a person who uses heroin a criminal and an addict who 
uses methadone a patient?’ ”  Despite its illogic, the statement mirrors how drug users are 56
treated and spoken about in America.  
!
 Stephens, 172.55
 Platt & Labate, 295.56
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 The justification for classifying heroin as a Schedule I drug is that has a high potential for 
abuse and no medical benefit has been discovered. This rationale contradicts the idea of opioid 
addiction as a disease: if the U.S. were to truly believe that addiction was a disease, the treatment 
of opioid addiction with heroin would be recognized as a medical use. This acceptance would 
allow heroin to be reclassified as a Schedule II drug, legalizing its prescription and normalizing 
its use as a medical treatment for dependence. Alas, this is not the case. As we will see later on, 
the heavy stigmatization of addiction—and, more specifically, of heroin—in America has much 
influence over the way we view and treat patients who are dependent. Much of the stigma is 
rooted in the biology of addiction and the way in which it is classified. 
!
B. Heroin Dependence as a Scientific Process 
 Heroin, an opiate, is derived from the morphine chemical found in  poppy plants.  When 57
orally ingested, intravenously injected, or nasally inhaled, it affects the brain by binding to 
receptors that produce a euphoric high.  These drugs “primarily affect the central nervous 58
system. That is, they influence mood, perception, and behavior through their actions on the 
brain.”  59
!
 Intravenous injection of heroin is the quickest, most efficient route to the brain.  It 60
produces the most immediate high and, due to the direct nature of the bloodstream, less of the 
 National Institute on Drug Abuse. “Heroin.” Drug Facts, NIDA.57




chemical is lost along the way, allowing the same high with less of the drug than other methods. 
This leads to many medical complications, including the transmission of blood-borne diseases 
via dirty needles and the susceptibility of open, post-injection wounds to bacteria found in the 
kinds of injection sites that would allow drug users to hide from law enforcement and the general 
public eye. Many of the health issues associated with opioid use have to do with unsafe, 
unsanitary intravenous circumstances, rather than with the drugs themselves, indicating that a 
partial response could provide a safe environment without delving into the complex legal and 
ethical issues of providing drugs to patients. 
!
 When someone uses a substance on a regular basis, their brain expects to receive the 
specific chemical and doesn’t produce enough—or any—of it on its own. “Over time, continued 
release of these chemicals causes changes in the brain systems involved in reward, motivation 
and memory. When these changes occur, a person may physically need the substance to feel 
normal. The individual may also experience intense desires or cravings for the addictive 
substance and will continue to use it despite the harmful or dangerous consequences.”  This 61
bodily panic manifests in the form of withdrawal symptoms. These symptoms are different based 
on the substance, but often include nausea, anxiety, insomnia, etc.  The only way to suppress the 62
symptoms is to give the brain what it wants: the drug. 
!
 American Addiction Centers.61
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 In addition to the monitoring of safe, healthy addictions that allow patients to participate 
in society, heroin maintenance “would also insure that addicts are getting drugs of assured 
quality. By making the drug so cheap, it would probably destroy the drug’s distribution and sales 
networks. Street crime would probably be significantly reduced since so much of it is driven by 
the price of drugs.”  Thus, opioid addiction has a number of social ramifications, and HAT has a 63
number of social benefits. 
!
C. Heroin as a Social Drug 
 Involvement with drugs has many social implications. In 1972, it was suggested that 
some people are more susceptible to opioid addiction than others because they fear they won’t 
receive positive reinforcement from the world around them, based on past experiences. “They 
seek forms of reinforcement more completely under the individual’s control, such as that 
provided by the injection of heroin.”  For those in marginalized communities who don’t have 64
total control over much in their lives like jobs or wealth, thanks to the United States’ societal 
inequalities and systematic oppression, initial heroin use is sometimes the only way to make a 
conscious choice to change a current mood or mindset.  
!
 Another theory argues that initial drug use is more actively due in part to socialization 
and the determination of normative behavior: certain peer groups, like the subcultures described 
by Richard Stephens, define a set of norms that don’t always align with those of the larger 
 Stephens, 171.63
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society, and members of those groups are expected to live with the associated norms in mind.  65
“Deviance is goal-directed learned behavior for seeking success or for coping with failure. When 
conforming behavior has failed to achieve the desired goals, alternative behaviors will be 
explored, some of which will probably be deviant.”  President Trump and his opioid 66
commission call for a far-reaching media campaign to scare people out of the desire for initial 
use of drugs, yet the research shows, quite interestingly, that “these campaigns often fail—or, 
worse, actually lead to more drug use by making drugs an attractive sign of rebellion or 
triggering curiosity about drugs that kids and teens previously didn't know existed.”  Certain 67
individuals make a point to go against society’s norms, engaging in behavior such as the 
consumption of illicit drugs. Others simply feel they have no place in society and no other way to 
feel the euphoria that accompanies narcotics.  
!
 Harm reductionists argue that current U.S. prohibitionist drug policies are influencing 
initial use. “The more drugs are tabooed and forcefully repressed, the more its users will tend to 
be marginalized, criminal, bearers and sources of diseases and the more the world of drug use 
will offer attractive alternative routes to earning money, gaining social status, and living a 
meaningful life in deviant subcultures.”  They don’t have access to the legitimate means that 68
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would allow them a satisfactory natural high from daily life, so they come to expect it from illicit 
substances. 
!
D. Addiction as a Socioeconomic Issue 
 Dr. Potee debunks the myth that opioid addiction appeared out of thin air in the late 
1900s. “Addiction is not new…opiate addiction has been a problem in many communities for 
decades, I just think it’s been swept under the rug or ignored because it’s been in urban settings 
of people who didn’t have as much power.”  She remarks that, lately, opioid addiction has 69
begun to transcend class divisions, popping up in every community and subsequently rising to 
the top of societal awareness. The recent social response to opioid addiction is partially due to 
the racial identities of those affected: in the past decade or so, opioid use and abuse has been 
largely attributed to white, lower- to middle-class Americans. The white parents of white people 
who are dependent on opioids have more of a voice in society due to their race, and are more 
often able to raise funds and awareness once one of their own has passed away of an overdose. 
However, parents aren’t the only ones fighting to end this epidemic. Health professionals, 
politicians worried about their addicted constituents, and citizens who are surrounded by 
addiction-based struggle and death in their daily lives are all involved in the search for a 
solution. 
!
 This victim-centered activism stands in stark contrast to American opinions regarding 
drug use and addiction in years’ past. Prior to the current opioid issue, drug use in America was 
 WGBY[Springfield, MA].69
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primarily attributed to low-income, urban communities of color. Author Michelle Alexander 
exposes the racist motivations behind the war on drugs, emphasizing that black people are 
thought to use and sell drugs more often than white people, purely based on stereotypes. These 
misconceptions are severely harmful for black communities, for they’ve resulted in alarmingly 
high rates of arrest. In fact, “in some states, black men have been admitted to prison on drug 
charges at rates twenty to fifty times greater than those of white men.”  This movement of mass 70
incarceration that persists today led to overflowing prisons and increases in the wealth and 
education gaps that divide black and white Americans. “Nationwide, the rate of incarceration for 
African American drug offenders dwarfs the rate of whites.”  This disparity mirrors the general 71
sentiment surrounding substance use, even though white Americans are more likely to have used 
illicit drugs than black America.  Since black people and drugs are over-criminalized, the prison 72
population is far from representative of the drug-using or general population as a whole.  
!
 Fueled by racist presumptions, society became desensitized to the issues accompanying 
addiction, and it came to view drug use as nothing more than a personal choice. Once white 
America felt that opioids had infiltrated its communities and homes, it finally decided to speak 
out and ask for help for those affected by addiction, more often blaming drug use on fate and 
unfortunate circumstance as opposed to the direct blame that has historically been placed on 
black and latinx users.  
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 Recent statistics show that, while heroin is in fact killing white people at a higher rate 
than black people, the latter population is experiencing a steep rise in overdose death rate that 
may soon surpass that of white U.S. citizens.  There is a fear among those who acknowledge 73
this racial disparity that, once white communities catch wind of the narrowing gap, the national 
movement will slow and those who are addicted will largely be forgotten. It will be important for 
white America to continue their fight, even if the numbers suggest that its young adults should no 
longer be the main focus of public health efforts. 
 Josh Katz and Abby Goodnough, “The Opioid Crisis Is Getting Worse, Particularly for Black 73
Americans,” The New York Times. 
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 Depicted in the above figure is the fact that, though rarely addressed in the media or 
public conversation, the overdose death rate of American Indians is comparable to that of white 
Americans. The historic and current lack of recognition of indigenous populations, both in the 
U.S. and elsewhere, is a huge issue that is necessary to examine and denounce. However, I won’t 
expand on that here, for my focus in terms of race is on the division between white and black 
America and the historic depiction of drug use by black communities that is now being flipped 
upside down. 
!
E. European Experiences with HAT 
 Different countries define success differently when it comes to combatting drug 
addiction. Countries with the belief that illicit drug addiction is almost unavoidable are much 
more likely to adopt methadone maintenance policies and programs. Such programs allow for the 
possibility of abstinence, if the individual struggling with addiction is able to decrease dosage 
until they are no longer chemically dependent, but also allow individuals to continue their 
routine drug use in a healthier, safer way, with maintenance programs—including HAT. 
!
 As is often the case, the U.S. is behind most of Europe, this time in terms of its social and 
political attitudes towards drug use and abuse. Switzerland has had tremendous success with its 
HAT programs, and is typically looked to as the pioneering HAT expert. There is much to be 
learned from a thorough examination of the Swiss experience in the treatment of opioid 
dependence, but a definitive country comparison requires a critical eye. Switzerland and the 
!33
United States differ in so many ways, and a later explanation will go into detail about why they 
differ too much to draw an effective parallel.  
!
 Britain, though still different than the U.S., is much more similar than Switzerland in 
terms of demographics and national values. This allows for a cleaner comparison between the 
two countries. Specialized doctors in the U.K. have been prescribing heroin legally and regularly 
since the 1920s, when most addicted patients were middle-aged females who presented a 
minimal threat to the social order.  However, recent U.K. policy priorities have focused on 74
improving the efficacy of MMT rather than supplementing it with HAT, so they must believe that 
heroin isn’t an ideal drug for the treatment of opioid dependence. This switch could also be a 
result of the increasing prevalence of young males who were often criminals, and thus not seen 
as worthy of receiving such a risky treatment. 
!
 In order to counter the chemical nature of addiction and the collateral consequences, a 
public health response to addiction would need to foster safe intravenous use and provide 
medication that binds to the same receptors in the brain as the drug—but would ideally be non-
addictive and non-harmful. This is a lengthy and challenging checklist. However, it is my hope 
that through a thorough examination of the initiation and outcomes of HAT programs in other 
societal settings, it will become clear that America needs to do something to reduce the harm of 
opioid addiction that is ravaging communities across the nation.  
!
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Chapter 3 - Switzerland 
!
 Switzerland was the pioneer on the HAT frontier. This fits with Switzerland’s global role; 
HAT is a progressive technology that requires tolerance, optimism, and a penchant for 
considering the long-term—all qualities that Switzerland has exhibited time and again.There is 
much to learn about how Swiss HAT programs came to be, but due to international differences, it 
may not be the best standard from which to create a U.S. model. Nonetheless, its groundbreaking 
policy change warrants a tour of the Swiss network. 
!
A. Swiss Heroin Addiction 
 A substantial increase in drug use in Switzerland came about through mechanisms similar 
to those that spurred the U.S. problem. Overprescription in the 1960s led to excessive 
recreational use, expanding the black market.  This led to a sharp increase in addiction towards 75
the mid-1960s, though relative to the U.S., Switzerland had a very minor heroin addiction 
problem.  
!
 More recently, Switzerland lead the controversial push towards medication with heroin 
itself. “In the 1980s and 1990s Switzerland experienced an increase in opiate users and, as a 
consequence, a marked increase in health and social problems.”  Drug policy at the time 76
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followed the Swiss narcotic law, which was based strictly on prohibition of both drugs and 
injection equipment. “This policy could not prevent a steady increase in the incidence and 
prevalence of drug use, especially of heroin injecting and its sequelae (increase in mortality, in 
blood-borne infections, in drug-related criminality and in drug trafficking).”  There were over a 77
thousand residential treatment places for those struggling with addiction, though the treatments 
were all forms of abstinence therapy. Despite Switzerland’s wide range of drug treatments, the 
existence of an addicted population that wasn’t benefitting was exposed, alerting the country to 
its flawed policies and programs.  78
!
 Eventually, the violence and social burden of widespread urban drug use became 
intolerable, and Switzerland realized that it needed radical drug policy reform.  Scientists and 79
policymakers began to implement programs that would reduce the amount of harm that illicit 
substances brought to individuals and to communities. “The new policy introduced harm 
reduction as a 4th pillar besides prevention, treatment and law enforcement. It also called for 
innovative approaches in all pillars, including medical prescription of heroin.”  HAT’s position 80
as an additional pillar indicates that it was never meant to replace preceding methods. “The four 
pillars are not to be understood as isolated areas of intervention. Rather it is the case that each 
pillar interacts with the others in several different ways.”  In order to make room for HAT, some 81
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of the emphasis on each of the other three methods needed to shift, but none of the alternatives 
were dropped entirely. This “4th pillar” rhetoric can be very useful when it comes to conveying 
the importance of an integrated public health response to a bipartisan crowd, for it reassures the 
public that other forms of treatment—and even accountability—will remain in place. 
!
B. PROVE: the ground-breaking study 
 In 1994 the Swiss Academy of Medical Sciences’ supra-regional ethics committee 
approved a study that would monitor the prescription of medical grade heroin and the provision 
of safe injection spaces for those whose addiction was persistent.  It was called PROVE, which 82
combines the beginnings of the German words for “project” and “prescription.”  The study 83
followed and compared patients using a few types of medical therapies, but “the essential feature 
and innovative element was the use of diamorphine as a medicine for substituting street 
heroin.”  The primary goal of the prescription program was to reach people with longstanding 84
dependencies who failed to complete other MAT programs.  Still, the overarching goal for the 85
long term was abstinence, but the Swiss program was founded on the understanding that 
continued drug use is almost—if not entirely—impossible to eradicate.  86
!
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 One of the common misperceptions regarding HAT is that any drug user could access 
subsidized heroin with little to no resistance, regardless of their intentions to quit. The PROVE 
study sought participants with specific eligibility requirements to minimize the possibility of 
such misuse. It only accepted injectors with a record of multiple unsuccessful attempts at other 
treatments.  These guidelines were put in place to separate people who have been addicted for a 87
while and have repeatedly sought help from those who may have just begun use and are hoping 
only to get high and not to rid themselves of a painful addiction. To earn the public’s trust in the 
efficacy and exclusivity of the treatment, policymakers framed the HAT guidelines as more strict 
than the guidelines for treatments already in place, including those for MMT.  88
!
 The findings of PROVE suggested that the implementation of national HAT programs 
would substantially benefit Switzerland as a whole. The study found significant changes in a 
number of areas, including decreased illicit drug use, improvements in health status, a reduction 
in crime, and more social integration of patients.  These conclusions challenge other 89
misperceptions that the public tends to have about drug addiction and HAT as a response. For 
example, many critics believe that prescribing heroin at no cost would increase drug-related 
crime. What they’re missing, though, is the fact that drug-related crime stems primarily from the 
high cost of black market heroin, driving some people who are addicted and unemployed to seek 
out alternative methods of acquiring their drug money. When clean, uncut heroin is provided to 
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communities through medical channels, users have no longer have the motivation to threaten or 
steal from the surrounding communities.  
!
 Additionally, PROVE was “evaluated by social, medical, pharmacological, economical 
and criminological studies and showed positive results.”  Despite widespread opposition to 90
funding the prescription of heroin to those who are already addicted to the drug, PROVE found a 
positive cost-benefit ratio of one to two.  As for the opioid-dependent individuals, follow-up 91
monitoring found high long-term retention of HAT, and of those who left the program before 
completion, many transitioned to other treatments or even abstinence.  A year into the study, 92
74% of participants in the heroin treatment program were still enrolled, compared to 29% of 
those on methadone.  93
!
C. The Official Implementation of HAT 
 Following the release of PROVE’s results, the Swiss federal government implemented 
HAT as a regular treatment option.  Further research is still being funded and executed, so as to 94
optimize the program for Switzerland and other countries who are interested and willing enough 
to give it a chance. For instance, researchers are looking into immediate and slow-release oral 
morphine and heroin tablets, and their performance when compared with the more common 
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injectable heroin.  Perhaps this would solve the aforementioned dilemma regarding heroin’s 95
short half-life and the obstacle it presents to those who struggle with addiction and employment. 
!
 In general, the results of the PROVE study indicate that HAT programs, at least in 
Switzerland, were successful for the target group. The prescription and administration of medical 
grade heroin succeeded in keeping most participants from resorting to illicit heroin, and “in 
November 2008, Swiss citizens voted on the 2nd revision of the Narcotic Law, which included 
the heroin maintenance treatment. It was well accepted.”  This was a paradigm shift for 96
Switzerland. In some ways, it was a total transformation. But it was founded on preexisting 
tolerance and openness, and was pushed along by a number of factors. 
!
 PROVE’s initiation and success was made possible by Switzerland’s unified society. The 
clear communication between the scientific and political communities was vital to the project 
and the resulting policy work. “This was facilitated by the Swiss direct democracy system. 
Sustained dialogue between researchers and the users of research enhances the likelihood of 
research affecting policy.”  Further, the Federal Office of Public Health implemented a number 97
of measures to quell the rise in drug use and abuse. The World Health Organization endorsed the 
positive results of PROVE, inspiring the Federal Government to pass an executive order that 
would act as legal justification to continue HAT for the target group. The integrated HAT 
programs were then financed by health insurance, which is funded by a number of sources, 
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including individual contributions and tax payments. The Swiss Federal Department of Home 
Affairs created the expert Schild Commission, a network of allied actors itself, in 1996 to revise 
the existing narcotic law. This presentation of knowledge got many more groups on board, for 
“after a formal consultation of the Schild Commission report by the authorities, the majority of 
cantons, parties, and expert organisations expressed acceptance of the medical prescription of 
heroin as an option for therapy and harm reduction practice.”  98
!
 Perhaps most importantly, the government organizations were able to convince citizens of 
the program’s success and the importance of its implementation. “The Swiss referendum 
democracy requires a considerable degree of citizen engagement and participation,” which 
means that the general public was accepting of HAT and thus it was in agreement with its 
government representatives.   99
!
D. A Network of Actors 
 All of the collaboration between groups indicates a strong sense of interconnectedness; 
Switzerland’s government organizations and other societal bodies can be imagined as a web with 
connecting threads passing from each individual to many others. With the experimentation and 
implementation of HAT in Switzerland, “a harm reduction advocacy network emerged, where 
health professionals, social workers, law enforcement agents, judges, lawyers, journalists, 
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politicians and others contributed to shaping an alternative to the prohibitionist policy model.”  100
In other words, Switzerland proved to successfully enroll and construct its network of allies 
when used as the context for HAT, allowing the technoscience to maximize its success. 
!
 There were many actors at play in the radical reform that Switzerland endured in the 
1990s. The aforementioned federal departments all played a significant role in the proposing and 
passing of relevant policies. Others were public health organizations: the Medical Association 
advocated for the provision of sterilized injection equipment, the Red Cross facilitated blood 
testing and immunization for diseases transmitted through the sharing of needles, and teams of 
EMTs prevented many fatal overdoses during administration.  Additionally, “a specialised 101
NGO for risk-free use of drugs was set up and opened a low-threshold methadone clinic, without 
obligatory counselling and urine controls, but with visual intake control to avoid diversion and 
overdose.”  Independent groups of citizens and parents would offer meals to users on the 102
streets and in parks in a less organized but no less supportive way.   103
!
 Some actors influenced the network in ways that didn’t require concrete policy changes 
or medical initiatives. The Social Department in the City Administration helped to normalize 
drug use and reduce surrounding stigma by changing “from a repressive attitude against 
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rebellious and drug using youth to an active policy of supporting measures to prevent health and 
social deterioration of users.”  Furthermore, the City Government began to actively promote 104
the prescription of heroin to those with chronic addiction, eventually fueling the Federal 
Government’s adoption of the same view in 1991 when the harm reduction pillar was added to 
Switzerland’s drug policy framework.   105
!
 In addition to all of the groups and individuals who worked for change in Switzerland, 
this specific network contains a number of non-human actors called actants by ANT aficionados. 
These actants are essentially enrolled by the actors in the network in hopes of building and 
strengthening alliances, which in turn will strengthen the case for harm reduction strategies.  The 
recruitment of an actant—epidemiological change, for example—by actors such as public health 
officials, or parents whose children use drugs could be considered a driving force behind the 
other interactions and changes in the network.  Similarly, the excessive violence, drug markets, 106
death rate increases, and general drug use each reinforced the human actors’ fight for change.  
!
 All of the relationships between actors were built, strengthened, and used for policy 
change within the span of a decade. The vast collaboration between actors was “driven by the 
unacceptable realities clashing with the cherished self-image of professionals in the health and 
social sector of being competent and efficient in meeting new demands.”  107





 This might seem like a solid case for HAT implementation anywhere, were it not for one 
thing: Switzerland is unique. It prides itself on qualities such as collectivism, positive 
communication, and, while perhaps more subtly, on homogeneity as well. Maybe Switzerland 
doesn’t encounter the same stigma surrounding addiction as the U.S. because it never had the 
racially-polarized drug history that skewed American perceptions. Michelle Alexander reminds 
readers that a society is a manifestation of its inhabitants: 
We could seek for them the same opportunities we seek for our own children; we could treat them 
like one of ‘us.’ We could do that. Or we can choose to be a nation that shames and blames its 
most vulnerable, affixes badges of dishonor upon them at young ages, and then relegates them to 
a permanent second-class status for life.  108
To Alexander, to myself, and to many others, the U.S. has chosen the latter option, blaming and 
destroying target populations so as to maintain a hierarchy full of toxic power dynamics. The 
former characteristic might apply to Switzerland when it comes to the unaddicted and addicted 
populations, but racially speaking, it isn’t heterogeneous enough to constitute an ‘us’ and an 
‘them’ in the same way. 
!
 Attempting to contrast Switzerland and the United States with knowledge of their 
differences is essential to drawing appropriate conclusions from the comparison. We could 
approach this process with their relative positions in mind and likely still gain insight as to the 
potential role of HAT in America. However, to ensure that we’re looking at a more complete and 
accurate picture, we shall ground the two extremes by looking at Britain and its relationship with 
addiction, treatment, and supportive collaboration.  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Chapter 4 - Britain 
  
 Switzerland’s smooth transition from successful study to political practice was made 
possible by the dense network of actors all working for the reduction of harm caused by heroin 
addiction. Most countries do not have such a stable network that functions in favor of HAT. 
Britain, a country in which heroin has been prescribed both as a pain medication and as a remedy 
for addiction, has had a slightly different approach than Switzerland when it comes to harm 
reduction. Perhaps HAT hasn’t been as widely successful and prominent because the British 
network isn’t as supportive of the particular technoscience. 
!
 This makes Britain a candidate for comparison with the United States. Switzerland and 
America don’t have quite as much in common, so it’s unlikely the U.S. will adopt the Swiss 
practices without major readjustments. Britain may be a more accurate contender for a few 
reasons. First, it is more racially diverse than Switzerland and, while it doesn’t compare to the 
U.S., it provides a more moderate comparison within an issue that is racially charged.  It also 109
has a larger percentage of urban dwellers, again more closely paralleling the U.S. than 
Switzerland does in that category.  Additionally, at least five British HAT studies used heroin 110
doses that were up to four times lower than a study of dosage regimes in Switzerland.  The 111
lower doses are more likely to be accepted and incorporated into any potential U.S. program, 
since the approach already faces so much resistance. Lastly, Britain’s National Health Service 
 “Field Listing: Ethnic Groups,” CIA World Factbook.109
 Ibid.110
 Gschwend et al., 47.111
!45
(NHS) itself seems to reflect a strong preference for abstinence-based methods, similar to the 
U.S. mindset.  112
!
A. British Heroin Addiction 
 A brief examination of Britain’s history with heroin addiction and treatment exposes the 
way in which the country experienced the inverse of Switzerland’s radical transformation of 
political and social mindset, leaving Britain in the same old paradigm that is less conducive to 
progressive changes in treatment. Since the 1920s, British physicians have been prescribing 
diamorphine to rid patients of addiction and to remedy other afflictions.  In 1926, a royal 113
commission chaired by Sir Humphrey Rolleston classified drug addiction as a medical 
problem.  This declaration allowed the Rolleston Commission to successfully prevent the 114
police from interfering in the relationships between patients and their physicians.  As a result, 115
physicians were able to treat patients openly and completely, and likely saw more patients due to 
an increased sense of comfort and immunity. 
!
 Britain’s history of prescribing—and maintaining—heroin dosages for patients with 
addiction might imply that their support for harm reduction approaches is one of the oldest 
around. However, their heroin prescription programs, though old, don’t have the necessary social 
and political support that would allow them to help the population that could benefit 





significantly. The numbers indicate that the population addicted to heroin and the proportion of 
those dependents seeking MAT have increased in recent years. Despite those steady increases, 
the role of any sort of treatment by opioid injection has actually decreased, and experiences a 
much smaller frequency of new patients than it did a decade ago.  This is most likely a result of 116
a change in mindset, as was Switzerland’s policy change. Though in this case, harm reduction 
was replaced by a prohibitionist movement that was remarkably similar to the case in the United 
States.  
For whatever reason, the British decided to follow the lead of the United States in setting up drug 
treatment centers, and we convinced them that emphasizing total abstinence was the way to go…
Prices of drugs skyrocketed, crime and violence increased, and so did the number of people in 
prison and the number of deaths from drug overdoses.   117
Britain observed a shift in mindset towards addiction in the same way that made the U.S. turn its 
back to those with drug dependence. Originally, it was middle- and upper-class women and 
professionals using in the privacy of their own homes—a situation that didn’t cause societal 
alarm.  “Concern mounted in the 1960s when the profile shifted toward marginalized young 118
men using heroin in a way that was more akin to the situation in the United States.”  119
Preconceived notions of the people with addiction prevailed and the demographics of the user 
population became less forgiving and more threatening; the perfect target on which to blame 
society’s problems. 
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 Even with a general recognition of these inequalities, some might think that the 
observation of these negative effects would inevitably induce a dramatic policy change, like the 
way in which Switzerland experienced a dramatic paradigm shift after PROVE. However, “the 
reluctance to prescribe heroin remains the case today; less than 1 percent of those being 
maintained on an opiate receive heroin (Stears 1997).”  Such a minuscule percentage barely 120
begins to cover the proportion of users who can’t find success with methadone therapies or other 
treatments that don’t incorporate diamorphine itself. 
!
B. RIOTT: the British trial 
  Britain’s Randomised Injectable Opioid Treatment Trial (RIOTT) began in 2005, 
followed by the publication of its results in 2010. Its primary goal was to compare the safety, 
efficacy, and cost-effectiveness of different injectable opioids, diamorphine and methadone in 
particular, to the more standard oral methadone treatment.  As in Switzerland, Britain’s heroin 121
prescription targeted only those in methadone programs who hadn’t ceased illicit heroin use 
throughout the course of treatment.  In other words, they had been unable to complete the 122
programs successfully, so they were given a chance at an alternative approach to better health.  
!
 The conclusion of Britain’s RIOTT study was similar to that of Switzerland’s PROVE: 
“recent British clinical guidance indicates that IOT [injecting opioid treatment] should be a 
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second-line treatment for those patients in high-quality oral methadone treatment who continue 
to regularly inject heroin, and that treatment be initiated in newly-developed supervised injecting 
clinics.”  The last clause pertains to the monitored location and sterilized tools that assist with 123
the prevention of overdose deaths and the spread of intravenously-transmitted diseases. Safe 
injection sites are another harm reduction measure that, when used with or without the 
prescription of medical diamorphine, drastically improve a community’s drug-related health by 
reducing overdose deaths and cutting the risk of diseases that might be transmitted through the 
use of unsanitary needles and injection environments.  124
!
C. The British Network 
 As in the U.S., current British programs aren’t finding the necessary success.The British 
network, as outlined here, consists of many actors: law enforcement, the government, doctors, 
the general public and those who struggle with addiction. In the U.S., the relationship between 
people with addiction and every other group is negative and condescending towards the ill, thus 
fueling the cycle of their addiction. In Britain, the actors have similar goals—safety and good 
health for those who need help—and thus they collaborate well, accepting and fulfilling the roles 
imposed on them by the circumstantial actor world. Not only does that approach save and 
improve lives that are already dominated by addiction, but the positively linked support network 
would help to quell the spread of initial use. However, Britain’s Americanized mindset might be 
its downfall when it comes to its reluctance to implement harm reduction strategies such as HAT. 
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The NHS website itself notes that most treatment programs available in the country “start with 
detoxification and medically-managed withdrawal, often considered the first stage of 
treatment.”  Though the site also reaches out to those with more challenging dependences—“if 125
you’re not ready to stop, you can still get help with staying safe and healthy”—it declares that 
both maintenance an detoxification programs involve a “switch from heroin,” rejecting the use of 
HAT on an official, advertised level.  126
!
 All hope is not lost for that portion of the addicted population, however. Though the 
network isn’t constructed in the most supportive fashion, Britain possesses a mindset conducive 
to the effective implementation of HAT. In general, the British “are sophisticated enough to 
understand that effective drug education must encourage young people to develop their own 
views about drugs and make informed decisions about their own and other people’s drug use.”  127
Initiatives are sprouting up at the local level, and some national studies have been conducted in 
an attempt to support a more integrated diamorphine prescription program. “One of the 
innovations that has been developed in Britain is the Healthwise Program in Liverpool, which 
recognizes that prevention must focus on specific risks rather than unattainable goals, regardless 
of how politically useful those goals might be.”  The recognition that drug use and demand 128
won’t just disappear in an instant is a vital step towards implementing preventative and 
responsive harm reduction measures. The aim is not to ignore the topic and hope that, as a result, 





no one learns about drugs and their dangers or the treatments that might be available once 
addicted. Rather, the aim is to provide accurate, comprehensive information and prepare a 
maximal amount of people to make healthy, responsible choices surrounding drug use.  129
!
 Britain, while more successful than the U.S. in terms of the efficacy of HAT in the 
national actor-network, doesn’t quite have the support that’s found in Switzerland. Its 
sophisticated understandings and innovations indicate the presence of an appropriate harm 
reduction mindset, but Britain’s network includes the addition of an influential United States, a 
node that tugs on the web just enough to let HAT slip through the cracks. This failure to 
sufficiently support HAT allows us to think critically about possibilities for the future of 




Chapter 5 - The Plausibility of HAT in the United States 
!
 Each of the three countries examined here had a different reaction to discovering that one 
of the roots of its respective addiction issues had to do with the medical accessibility of drugs. 
Once they had promoted the prescription of diamorphine to treat heroin addiction, “England 
chose to allow private physicians complete discretion in maintaining addicts on heroin, partly 
because the policy makers believed addicts had become addicted in the course of medical 
treatment (Lidz, Lewis, Crane, and Gould, 1975).”  This is almost identical to Switzerland’s 130
feeling of obligation to continue prescription for fear of depriving patients of what they had 
become addicted to in the course of legal medical treatment.  
!
 The U.S. responded differently when it discovered that opioid prescriptions quadrupled 
between 1999 and 2010, drastically reducing the quantities and frequencies of prescription, 
which drove many addicted patients to seek illicit heroin to quell their symptoms of withdrawal. 
All three countries have, in a way, given their patients heroin, but for the European countries, it 
was to make addiction more bearable, whereas the case in the U.S. was indirect and 
unintentional, and resulted in a raging epidemic. 
!
 A Latourian approach might argue that the success of HAT is determined entirely by the 
construction and strengthening of the social networks that string each country together. If that’s 
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the case, sociopolitical comparisons of both Switzerland and Britain to the United States should 
provide insight into whether or not HAT is a reasonable response to the U.S. opioid epidemic. 
!
A. Switzerland vs. the U.S 
 The three aims of Swiss drug policy are 1) to reduce the use of drugs, 2) to reduce the 
negative consequences for users, and 3) to reduce the negative consequences for society.  Was 131
PROVE successful in these goals of reducing drug-related harm in Switzerland? The study, 
supported by the vast majority of the nation, says yes. Can the success of PROVE be transported 
overseas and onto U.S. soil? This is where the controversy lies. On one hand, the belief that such 
a change in healthcare is possible in all advanced, industrialized nations says that it can 
absolutely be a solution to the current American opioid epidemic. Many “believe that a 
reasonable case can be made for a U.S. trial…The downside risks of a trial in the United States 
seem slight and the potential benefits, substantial.”  But limited resources and a partisan 132
government force us to wonder whether or not this is realistic.  
!
 Will the U.S. be able to look past the risks and focus on the long-term societal benefits? 
Unfortunately, some argue that the U.S. and Switzerland are far too different. In Switzerland, 
“the FOPH has the legal mandate to promote scientific research into illegal drugs.”  The 133
existence of this requirement showcases the inherent and enforced relationship between the 
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government and the rest of society, a characteristic that proved useful with the implementation of 
drug treatment policy.  
!
 To supplement the concrete laws that reinforced positive communication and 
collaboration between Swiss actors, Switzerland’s initiation of PROVE required a certain level 
of mutual trust between its citizens and government: trust in the study’s strict eligibility 
requirements, trust in the science behind addiction and heroin itself, and trust that those who seek 
treatment are genuinely reaching out for help. Based on the way Americans view and treat 
opioid-dependent persons, it is doubtful that the U.S. has the capacity for such trust. First of all, 
the presence of stigma and the national mindset vary drastically. In Switzerland, HAT has existed 
for decades already, indicating that the public has been and grows more accepting of addiction 
and of those afflicted. “Swiss pragmatism and American idealism may derive different 
conclusions from the same set of results about the effects of providing a highly addictive drug to 
those who already crave it.”  In general, the American network possesses an abstinence-based 134
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 This figure shows the relationship between the three countries with regards to two 
important national qualities, measured by Dutch social psychologist Geert Hofstede.  As the 135
graph on the left suggests, Switzerland has a much higher orientation for the long term than the 
U.S., making it much more likely to seek out harm reduction strategies. The second graph shows 
that the U.S. values individualism, or personal responsibility for one’s actions, much more highly 
than Switzerland, which aligns with the arguments surrounding America’s stubbornness towards 
helping addicted patients. In both measures, Britain scores between the two others, providing 
support for its position as an intermediary in this thesis.  
!
 The countries’ mindsets also differ when it comes to the categorization of drug use in 
general. Switzerland sees it as a health issue, with a cure to which everyone has a right. “Once 
the [Swiss] government had provided heroin addicts with the drug, it incurred a continuing 
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at: https://www.hofstede-insights.com/product/compare-countries/.






obligation to maintain those addicts as long as they sought heroin.”  This way, the government 136
is never the source of painful withdrawal symptoms. The U.S. is unlikely to prefer the notion of 
“maintenance” to that of “abstinence” any time soon. Abstinence has always been the primary—
and often only—goal of the American fight against heroin addiction. Thus, it is difficult to justify 
the maintenance of a certain dosage rather than a diminishing dosage that will eventually lead to 
ceased consumption.  
!
 To be fair, the Swiss have never encouraged recreational drug use and, even at the time of 
PROVE’s initiation, “opinions and attitudes regarding drug policy issues were not unanimous 
throughout the country.”  Many were torn between supporting the community and blaming the 137
addicted. “The Swiss citizenry were unwilling to be very tough about enforcement but also were 
offended by the visibility of the problem, arguably an important consideration in Swiss drug 
policy.”  However, their behavior seems a bit more forgiving and optimistic when compared to 138
that of the United States.  
!
 Would it be difficult to implement HAT programs in the U.S. as a supplementary 
treatment option for people caught up in today’s growing epidemic of opioid addiction? 
Absolutely. It is difficult to imagine the prescription and subsidization of a drug so widely 
despised. But if the U.S. has any desire to listen to and learn from the success of PROVE in 
Switzerland, there is a possibility that HAT might eventually be an American reality.  
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The Swiss experience demonstrates that in a wealthy society which values order and sobriety, it is 
possible to build a base of popular support for heroin maintenance. On the other hand, 
Switzerland is a somewhat paternalistic society, and its citizens may be less troubled than are 
individualistic-minded Americans by some of the normative issues discussed here, although there 
is little positive evidence to support that speculation.   139
Though there are minimal data that address the country comparison directly, this goes to show 
that, since Americans aren’t that different than the Swiss, the U.S. shouldn’t have an issue 
implementing what worked in Switzerland more than two decades ago, and what continues to be 
an integrated component of its national healthcare. 
!
 In order to garner support for PROVE, Switzerland had to transform its views of 
addiction, leaving a majority of citizens somewhat satisfied, while others had to adjust to the 
methods with which they disagreed. The change in Swiss drug policy can be examined as “a 
competition between a prohibitionist and a harm-reduction coalition.”  The U.S. policy debate 140
may be too complex to be viewed in the same way; there are too many American actors whose 
mindset is somewhere on the spectrum between the two camps, and too many on the side of 
prohibition to be able to enroll enough allies in support of  harm reduction policies.  A harm 
reduction mindset requires the understanding that, in order to reduce the amount of collateral 
damage done to communities that contain drug users, “measures to prevent blood-born infections 
must override the inefficient belief in preventing drug use in an abstinence-only perspective—not 
only for the sake of users, but in order to protect the general population as well.”  It may seem 141
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effective to frame the issue as everyone’s problem, not just those who ‘choose’ to engage in drug 
use and related activity, but many American skeptics would likely blame those who interact—
sexually or otherwise—with drug users, regardless of their own personal record of drug use. 
People on the side of individualism will have a tough time adopting a harm reduction mindset in 
general, for they don’t see that the entire community is affected, regardless of the choices each 
person makes independently. 
!
 Switzerland prides itself on an overall sense of unity that allows the government, the 
general public, the scientific community, and other industries and institutions to collaborate and 
exchange information with each other. Article 15c of the Swiss Narcotics Act of 1975 says that 
“the Federal Office of Public Health (FOPH) has the task of supporting players active in the 
areas of prevention, therapy and harm reduction (cantons, communes, private organisations).”  142
This fuels Swiss technological and social progress. In the midst of a national crisis such as 
increased heroin addiction, that process is expedited. “Clear shared objectives and a common 
feeling of urgency brought the coalitions together,” driving a positive and productive exchange 
of ideas.   143
!
 One way to describe this is with the term knowledge brokering, which  “focuses on 
identifying and bringing together people interested in an issue in order to develop evidence-
based solutions.”  Unfortunately, the U.S. lacks this sense of togetherness, especially under the 144
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current administration. On April 22nd of 2017, a national “March of Science” was organized and 
executed as a result of the tension and conflict between the political and scientific 
communities.  The mere existence of the March demonstrates the United States’ inability to 145
maintain healthy relationships between those who do research and those who make decisions.  
!
 Requirements for productive knowledge brokering include: “organizing and managing 
joint forums for policymakers and researchers” and “building relationships of trust.”  Many 146
commissions and panels dealing with scientific issues are founded and facilitated by America’s 
Trump administration, and happen to contain few to no scientific experts that align with the 
scientific majority view. For example,  
In the United States political reaction to the Swiss trials was illustrated by hearings held by a 
House subcommittee. The subcommittee called as witnesses two doctors from Switzerland with 
long records of hostility to both needle exchange and heroin maintenance...No Swiss researcher 
or official associated with the trials was given an opportunity to testify.  147
This exclusion of key players from the discussion leads directly to the spread of misinformation 
and the omission of fact. The U.S. is a frequent suspect in this type of information manipulation, 
churning out skewed figures and reports based on a particular perspective.  
!
 Additionally, the American political divide is polarizing, unlike the Swiss pluralistic 
structure. Switzerland’s Federal Council is composed of the four largest political parties in the 
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country, allowing each party to be well-represented at times of decision-making. “In 1991, the 
Federal Council decreed a new national drug policy, backed up by a shared policy platform of 
three major political parties.”  The Swiss Federal Council’s political diversity suggests that, 148
once something is successfully approved and implemented, it must’ve been supported by three or 
four parties, rather than the dichotomous domination that occurs in the U.S. Externally, the 
government is a central part of the Swiss network, holding the web together by maintaining 
positive relationships with non-government bodies. “On the basis of its position in the structure, 
which gives it a national and international perspective, the federal government also acts as a 
moderator and coordinator in encouraging reciprocal voluntary coordination between the various 
players in drug-related fields.”  Whereas the U.S. government tends to use its power to widen 149
divides and enforce regulations, the Swiss government uses it to bridge gaps and connect various 
actors across the nation.  
!
B. Britain vs. the U.S 
 Britain, though perhaps a better tool for comparison, isn’t as similar to the U.S. as some 
might think. “The problem of addiction to opiates, especially heroin, is vastly larger in America 
than in the United Kingdom.”  A few questions arise regarding the nature of this statement: has 150
the discrepancy been consistent throughout history? or is it the result of their differing responses? 
is it related to Britain’s tradition of prescribing heroin? Would the U.S. benefit from adopting 
similar practices? A potential partial solution to this series of questions is that, “while many 
 Khan et al., 201.148
 Swiss Federal Office of Public Health, 14.149
 Trebach, 20.150
!60
observers have commented on the impossibility of comparing the U.S. experience with that of 
England because of massive cultural differences, Lidz et al (1975) believe the real difference lies 
in the type of policy each country has pursued in attempting to control heroin addiction.”  To 151
better grasp the fundamental differences between the two countries’ respective problems, it is 
necessary to look at specific societal aspects and investigate why they might differ from place to 
place.  
!
 The role of and restrictions on doctors in each society vary significantly. For example, the 
practices of doctors in the U.S. are dictated by the government much more than those in Britain. 
In the U.S, doctors must follow strict, up-to-date guidelines produced by various government-
controlled committees. The NHS, on the other hand, is a body independent of the British 
government, and thus “English doctors have the power to try a new clinical tack at any time. 
That power should be given to American doctors: to act on clinical hunches and to adjust them in 
the light of rational criticism and experience.”  This suggestion would likely face ethical and 152
political obstacles, especially since the past twenty years have seen an encouraged decrease in 
the prescription of opioids for pain. To legalize and medicalize heroin itself would be to 
backtrack, and that might ruin the image of the U.S. as a forward-pressing global leader in 
medicine and technology. 
!
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 The relationship between the legal system and the medical community is vastly different 
in the U.S. and Britain. For some people who are addicted, MAT or other legal treatments aren’t 
able to successfully keep them from committing crimes and seeking illicit substances. To some 
extent, individuals must be controlled so they don’t harm their communities, and if available 
treatments don’t work, appropriate police intervention can dampen the consequences of their 
behavior. In the U.S., police tend to invade clinics and interfere with the doctors’ drug-
prescribing practices that are only in place to help those who are addicted, and thus the two 
parties clash. In April 2018, the FBI raided a methadone clinic in New Jersey where patients 
were receiving MAT for their opioid addictions, simply because it “has long been considered by 
city officials to be standing in the way of downtown revitalization.”  However, when the 153
British authorities interact with patients, the medical experts and the police form a team to reduce 
harm, with the doctors sending risky patients “into the arms of the police” in a gentler, less 
abrasive way.  This is yet another depiction of how the network of actors in the U.S. suffers 154
from too many authoritative relationships, and that of Britain is woven together in a much more 
productive way.  
!
 When a British model of HAT was proposed as a new American policy, the U.S. Strategy 
Council on Drug Abuse didn’t hesitate to shut it down. “It was felt that legalized distribution of 
heroin would not substantially alter the recruitment pattern of new addicts.”  The overall goal 155
of the Council and it’s founding country is abstinence, so it took immediate issue with the British 
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idea of maintenance as a method of harm reduction. The council is a useful example that shows 
that, while the U.S. does construct networks around drug use and potential treatments, the 
network is oppressive rather than supportive, and its main goal is to maintain current structures 
of power. 
!
 This translation runs both ways, and while the British policy was proposed to and 
discarded by the U.S., the U.S. itself was busy exerting its influence over its transatlantic 
neighbor. Many would describe the U.S. network as toxic—riddled with dangerous power 
dynamics and distrust. Thus, Britain somewhat succumbed to this global power, falling into step 
behind it on the path to individualism and abstinence, while Switzerland maintained its national 
identity as a neutral and independently-minded country.  
!
C. Barriers to the Implementation of HAT in the U.S. 
 To hypothesize about the plausibility of implementing HAT in the U.S., it is necessary to 
ask a series of questions, addressing each step of the complicated process that turns an idea into a 
policy and, from there, into a practice. This process is not linear. It is guided by the actor-
network, allowing an idea, policy, and practice to interact with each component of the web. 
!
 Will the government have a fair exchange of ideas with the scientific community? As is 
evident from the examination of Switzerland, it is necessary to have a respectful, mutual 
translation in order to use research to propose and pass policies. The U.S. seems to be incapable 
of such a fair exchange. 
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 How would the U.S. respond to heroin’s overnight transformation from illicit to 
prescribed and subsidized? To facilitate such an abrupt change would be to discount the drug 
classification of heroin that has been supported for decades. It would be difficult to justify said 
switch, especially when the chemical makeup of heroin hasn’t changed at all. Furthermore, 
heroin has no medical benefit, other than for patients with addiction, beyond what other opioids 
can do for pain, so it’s removal as a Schedule I drug would require a restructuring of the whole 
classification system and the labeling of diacetylmorphine as Schedule II instead.  
!
 If politicians and citizens of the United States were willing to implement HAT of some 
form, how would it be funded? If it became a part of health insurance, though that system is 
complex, much of the funding would come out of tax payments. Given the recent passage of a 
regressive tax bill, it is unlikely that individuals will be interested in subsidizing heroin for 
people who are believed to be entirely at fault for their own situation.  
!
 When would the U.S. achieve “success” and what is the American definition of the term? 
At a minimum, it can be said that it isn’t the definition required of a harm reduction mindset. 
Switzerland and Britain—or at least a large part of each country—share the notion of a 
successful drug treatment program as one that reduces the number of people who are addicted 
and allows those who struggle with drug treatment programs to carry on healthy relationships, 
employment opportunities, and a relatively harmless daily routine. In the U.S., the view is 
largely that success implies abstinence on a national level. To implement HAT or other harm 
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reduction methods, America would need “a redefinition of successful outcome in drug treatment 
programs to focus on a return to productive life rather than remaining drug-free.”  156
!
 As is clear from a thorough exploration of America’s current political and social 
environments, it would be extremely difficult to implement HAT successfully in the U.S. at this 
moment. In order to do so, the U.S. would have to restructure the translations within the actor-
network, making it more stable and allowing information to flow both ways along each 
connecting thread. Right now, the stigma surrounding addiction is far too prevalent to allow for 
much support of a harm reduction approach, even though the so-called ‘epidemic’ continues to 
devastate communities across the country. 
!




 So is there a tangible solution to this issue?  When we break down the populations who 
need help in the form of large-scale initiatives, it becomes easier to determine what to do for 
each group. Stanford drug policy expert Keith Humphreys describes this as the stock and flow 
dichotomy. “On one hand, you have the current stock of opioid users who are addicted; the 
people in this population need treatment or they will simply find other, potentially deadlier 
opioids to use if they lose access to prescribed painkillers. On the other hand, you have to stop 
new generations of potential drug users from accessing and misusing opioids.”   With a line 157
drawn between those who need treatment and those who need preventative measures, it is 
possible to consider a solution with three main areas. The first area focuses on medical 
treatments that can be enrolled in the network through a series of translations. The second area 
focuses on the rhetorical changes that can be made by society; this desire is a bit more far-
fetched and long-term than the monitored prescription of MAT drugs, but will effect the 
implementation of both treatment and prevention initiatives. Lastly, I will include the 
aforementioned societal changes that will hopefully drive a decrease in initial use and thus 
addiction. This shift will likely happen over generations, so though I understand the urgent need 
for a ready-made solution,  I also feel it is important to look ahead at what will benefit us most 
down the line. 
!
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 Before the U.S. is ready to accept and encourage HAT as a supplementary treatment, 
there are some intermediate alternatives. Needle exchanges, or the distribution of clean needles 
to users who have their own substances, tools, and locations, help to prevent the spread of sexual 
and potentially lethal diseases. Safe injection sites provide clean, private places for users to inject 
their own drugs with clean tools and in a monitored setting. This also mitigates the spread of 
disease and the risk of overdosing alone in a filthy environment. Additionally, the privacy 
reduces the shame that many users feel when seen going into or coming out of a clinic, and 
reduces the visibility of drug use and its behavioral effects within the public eye.  
!
 Once we’ve lain the foundation for HAT by implementing said intermediate steps, the 
technology would be much more easily accepted than if it were proposed immediately and with 
minimal harm reduction policies already in place. It is less overwhelming to introduce a new 
framework bit by bit than to throw society into a new paradigm without preparation. If safe 
injection sites were to be more popularized, HAT would entail the mere addition of prescription 
diacetylmorphine. This way, both the users and those who are monitoring their use, know what 
the drug is and where exactly it came from, assuring those who use that the drug is pure and 
uncut with poisons such as fentanyl.  158
!
 As soon as we’re able to offer a maximal amount of options that are considered medically 
appropriate to treat opioid dependence, we can look to the broader issue of stigma and rhetoric, 
and how those have been known to significantly impede the implementation of harm reduction 
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strategies. Historic events have fueled our harmful language, weighing down words with 
negative connotations. One such example is “Reagan’s National Security Decision Directive, 
which declared drugs a threat to U.S. national security, and provided for yet more cooperation 
between local, state, and federal law enforcement.”  Along with Nixon’s association of drugs as 159
the primary public enemy of the American population, this reinforced the notion that drug users 
need to be controlled and pulled from society. We can begin to flip this negativity on its head by 
using medical terms such as “diacetylmorphine” rather than the more threatening “heroin,” or “in 
treatment” rather than “getting clean,” which implies that those who are currently using or 
addicted are dirty.   
!
 Following drastic adjustments in terminology, we can move on to addressing some 
deeper questions. If the issue at stake is opioid addiction, how do we define a successful 
accomplishment? Right now, the conversation seems to pinpoint addiction as the issue, but the 
more emotionally-wrought battle seems to be centered around the lives lost to overdose death 
and the loved ones who are left behind. Why don’t we measure our success in decreased death 
rates? If we were to change our mindset in this area, we would find immense success with HAT 
and other forms of MAT, because the data show that the presence of MAT programs is inversely 
proportional to the overdose death rate.  Though he hasn’t tried or considered HAT in 160
particular, Dr. Kitfield is one of the few actors in the U.S. network that measures success in this 
way. “Long before the heroin epidemic began to make headlines in Maine, Kitfield was 
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providing patients with medication-assisted addiction treatment.”  The MAT clinic “‘is opening 161
a door for people that makes recovery possible,’ Kitfield said. ‘I’ve seen life open up again for 
(patients). They start to feel good again. They can hold down a job. They stop dying.’”  162
Evidently, Dr. Kitfield adheres to a harm reductionist view in this sense, where the goal is to 
subdue the associated harms rather than eradicate addiction itself.  
!
 However, even if the goal were to eliminate addiction overall, we need to reconsider our 
definition of the disease itself. The definition of substance use disorder is dependent not just 
upon the physical drug dependence, but an additional behavioral manifestation.  
 The qualification for a substance use disorder is that someone is using drugs in a dangerous or  
 risky manner. So someone with an opioid use disorder would not just be using opioids but  
 potentially using these drugs in a way that puts him or others in danger...Basically, the drug use  
 has to hinder someone from being a healthy, functioning member of society to qualify as   
 addiction.  163
Thus, regardless of the goal, if we keep people from seeking out black market drugs, committing 
property crime, and overdosing, we’ve technically stopped addiction and reached the anti-
addiction goal for at least the population in treatment. Since the beginning of MAT studies, this 
finding has been the basis of the argument in favor of maintenance programs that don’t require 
sudden and complete abstinence. “So far as Dr. Dole and Dr. Nyswander could see, [the patients 
with opioid dependence] had become normal, well-adjusted, effectively functioning human 
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beings--- to all intents and purposes cured of their craving for an illegal drug.”  Addressing this 164
rhetorical and conceptual challenge would likely require a moderate shift in the national mindset, 
but would eliminate many hindrances to a harm reduction approach. 
!
  Let’s return to the issue of identifying a problem and its solution. Given the 
problem of heroin addiction, prohibitionists would say that dosage reduction, law enforcement, 
and mental therapies are all solutions—as a combination or independently. Harm reductionists 
would propose that MMT, HAT, or other maintenance programs should be included in the arsenal 
of treatment options as well.  
!
 However, even those who strongly believe in the potential of maintenance programs have 
hesitations. It is thought to be more of a downstream approach in that it responds to the surface-
level manifestation of a more deeply-ingrained societal issue. “As with methadone maintenance, 
one can claim that by providing a drug on a maintenance basis, one is treating only the symptoms 
of the ‘disease.’ The underlying root causes are not being dealt with.”  Rather than spending all 165
U.S. funding available to combat addiction on a cure that will reduce the prevalence of addiction 
before the onset, as the argument goes, we’re spending too much of the national energy and 
budget on the suppression of individuals who have already been damaged by drug use and the 





 Even the European programs that are successful and influential on one hand are 
fundamentally flawed on the other. For example, the British system is criticized for its failure to 
take a preventative action. Alan Massum, one of its critics, noted that “the British approach deals 
only with symptomatology and not with the causes underlying the use of drugs.”  To those 166
which share Massum’s views, the aforementioned ‘solutions’ are no such thing; rather they are 
merely treatments for individuals in the short-term.  
!
 How do we address a problem so large and destructive? We can begin by tracing the 
problem, opioid addiction, back to its roots in hopes of determining points at which to intervene 
prior to the onset of addiction. One theory behind initial heroin use is that the United States’ own 
policies and former actor-network, constructed in an attempt to remedy the epidemic, have 
actually contributed to widespread addiction in various ways. “After the passage of the Harrison 
Act, a major black market developed which supplied addicts with a variety of drugs, particularly 
the increasingly popular heroin.”  To counter this, we must provide heroin for a very specific, 167
needy population through government funding and physician practice, which would compete 
with the black market and offer cheaper, safer, more legal access to drugs, causing the black 
market to dissolve. This would be quite challenging, given the widespread opposition for the 





 Many studies that examine initial use of heroin “support the hypothesis that narcotics are 
first used with other persons.”  Opioids are often considered to be a social drug. Initial use 168
often occurs when an individual is—explicitly or implicitly—pressured by those with prior 
experience taking the substance, or when the individual has made a pact with another novice to 
use together. Breaking out of drug-using social circles might be one way to avoid being drawn 
back into the euphoria, but a way to accomplish this for addicted individuals without 
jeopardizing their liberties and relationships remains a mystery. 
!
 Aside from the black market and small social circles, American society has larger issues 
that contribute to its widespread struggle with addiction. “A society’s drug policy provides telling 
clues about how that society is coping, not simply with drug issues but also with such problems 
as poverty, race relations, and political conflicts.”  Every society faces internal inequalities, 169
but the United States in particular has a long history of discrimination and exclusion. A 
preventative technique that would target the issues surrounding deviant drug-using behavior 
would require a drastic reduction in the American wealth gap, improvements in race relations, 
and a fundamental restructuring of society. The end goal of such an approach would be to make 
everyone feel included and respected. “A truly successful prevention campaign would require far 
more ambitious efforts than those described here. It would require making sure that young 
people--particularly those from disadvantaged backgrounds--have a genuine opportunity to lead 





take a long time. One recovering patient, Chris Heide, explains his long-term opioid dependence: 
“The temporary high that I craved replaced my unresolved feelings of not belonging.”  For the 171
sake of society and its opioid-dependent members who face struggles like those in Heide’s past, 
it is worthwhile to examine and implement large-scale change such as this, no matter how far-
fetched it may seem.  
!
 The act of turning this causal factor into a solution is tricky. There will always be social 
groups that have conflicting ideals, morals, goals, norms, and other characteristics. But one way 
to minimize deviant behavior would be to normalize deviance itself. Dismantling the idea of a 
norm is the first step on the path to reducing the initial drug experiences that stem from a desire 
or a need to be deviant. The Netherlands has developed a reputation similar to Switzerland’s in 
that both countries are relatively progressive, collectivist, and demographically homogeneous, 
rendering it another appropriate tool for comparison. The Dutch parliament began to 
acknowledge and accept deviance in 1976 by enacting the revised Opium Act, which “is part of 
the Dutch drug policy framework that includes tolerance for nonconforming life-styles, risk 
reduction with regard to the harmful health and social consequences of drug taking, and penal 
measures directed against illicit trafficking in hard drugs.”  This system, as opposed to its 172
American counterpart, punishes only those who explicitly engage in the spread of addiction: 
traffickers and dealers. Those who use on an individual basis are treated as people who have 
made specific life choices, as everyone has, and whose choices require special focus on their 
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health and safety. Accepting ‘abnormal’ drug-using lifestyles helps to normalize the issue and 
eliminates much of the ostracism that leads to deviance and associated behaviors.  
!
 Changing America’s individualistic mindset is a substantial step in the right direction. 
Were individualism replaced by a more unified, communal outlook, the tension between 
individual responsibility and external causes—such as genetics or social environment—would be 
much less severe. 
If we acknowledge that genetics and environmental factors probably cause a portion of the 
population to be vulnerable to drug experimentation, abuse, and addiction, our drug control 
policies must necessarily change. But for the moment, while the science of drug abuse and 
addiction holds great therapeutic promise, the politics are self-defeating, punitive, and 
vainglorious.  173
Taking the fundamentals of ANT into account, we can identify addiction treatments as the 
technoscience and the drug policies by which they’re determined as actants in the larger network 
of socio-political interaction. When contextualized inside the American version of this network, 
the technoscience won’t be as effective in remedying widespread addiction. 
!
 It is possible to argue that, though the proposed societal changes are much larger than a 
steadily growing body of literature, or a coalition of heart-broken parents, or a team of medical 
experts, there is hope. Changes are being made at all levels. Trump’s new Health and Human 
Services Secretary, Alex M. Azar II stated that the agency intends “to correct a misconception 
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that patients must achieve total abstinence in order for MAT to be considered effective.”  The 174
FDA chief, Scott Gottlieb, defined MAT as the use of drugs to stabilize brain chemistry, reduce 
or block the related euphoria, relieve physiological cravings, and normalize the functioning of 
the body.  None of this indicates that total abstinence is the only accepted measure of success, 175
which is a step in the right direction, but harm reduction rhetoric is useless without action and 
access.  
!
 President Trump’s opioid commission, lead by Governor Chris Christie, has put forth 
over fifty recommendations for how to deal with the opioid crisis, yet “the commission does not 
say how much funding implementing its recommendations or talking the opioid crisis will 
require--leaving a huge question open, even as it argues that ‘Congress must act’.”  The 176
director of opioid policy research at Brandeis University, Dr. Andrew Kolodny, expressed 
frustration with the limited availability of and support for MAT programs: “we already have an 
effective treatment that people aren’t getting access to.”  Perhaps it would benefit a larger 177
population if we were to continue investing just as much—if not more—into MAT programming 
and access, rather than running our own studies on HAT for the percent of the population that fits 
within the target group. Either way, we need to do something more than what is happening now, 
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when immobility and harmful rhetoric are fueled from the top down, hindering our potential for 




“12 Step Programs for Drug Rehab & Alcohol Treatment.” American Addiction Centers, 2018, 
americanaddictioncenters.org/rehab-guide/12-step/. !
Adams, Abigail W. “Wiscasset Family Medicine Has New Owner, Founder Remains on Staff.” 
The Lincoln County News, 20 Sept. 2017, lcnme.com/currentnews/wiscasset-family-
medicine-new-owner-founder-remains-staff/. !
Alexander, Michelle. The New Jim Crow. New York: The New Press, 2010. !
Bernstein, Lenny. “At the Heart of Canada's Fentanyl Crisis, Extreme Efforts That U.S. Cities 




Bernstein, Lenny. “A Secret, Supervised Place Where Users Can Inject Drugs Has Been 




Blanken, Peter, et al. “Outcome of Long-Term Heroin-Assisted Treatment Offered to Chronic, 
Treatment-Resistant Heroin Addicts in the Netherlands.” Addiction, vol. 105, no. 2, 2010, 
pp. 300–308., doi:10.1111/j.1360-0443.2009.02754.x. !
Brecher, Edward M. Licit and Illicit Drugs: the Consumers Union Report on Narcotics, 
Stimulants, Depressants, Inhalants, Hallucinogens, and Marijuana -Including Caffeine, 
Nicotine, and Alcohol. Little, Brown, 1988. !
Callon, Michel et al., eds. “Glossary.” Mapping the Dynamics of Science and Technology: 
Sociology of Science in the Real World, Palgrave Macmillan, 1986. !
Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in 
Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. HHS 
Publication No. (SMA) 12-4214. Rockville, MD: Substance Abuse and Mental Health 
Services Administration, 2005. !
“Chasing Heroin.” PBS Frontline, 23 Feb. 2016. !
“Compare Countries.” Hofstede Insights, www.hofstede-insights.com/product/compare-
countries/. 
!77
Courtwright, David T. “The Prepared Mind: Marie Nyswander, Methadone Maintenance, and the 
Metabolic Theory of Addiction.” Addiction, vol. 92, no. 3, 1997, pp. 257–266., doi:
10.1046/j.1360-0443.1997.9232572.x. !
Cressman, Darryl. “A Brief Overview of Actor Network Theory.” Simon Fraser University, 2009. !
Eardley, Nick. “Heroin Abuse - Does the UK Still Have a Problem?” BBC News, 2 May 2014, 
www.bbc.com/news/uk-27235470. !
Eyre, Eric. “Trump Officials Seek Opioid Solutions in WV.” Charleston Gazette-Mail, 21 Nov. 
2017, www.wvgazettemail.com/news/health/trump-officials-seek-opioid-solutions-in-wv/
article_52c417d8-16a5-59d5-8928-13ab073bc02b.html. !
Fischer, Benedikt. “Heroin-Assisted Treatment as a Response to the Public Health Problem of 
Opiate Dependence.” The European Journal of Public Health, vol. 12, no. 3, 2002, pp. 
228–234., doi:10.1093/eurpub/12.3.228. !
Fischer, Benedikt, et al. “Heroin-Assisted Treatment (HAT) a Decade Later: A Brief Update on 
Science and Politics.” Journal of Urban Health, vol. 84, no. 4, 2007, pp. 552–562., doi:
10.1007/s11524-007-9198-y. !
“Franklin County Opioid Treatment Center.” WGBY [Springfield, MA], 13 Apr. 2016. !
Grapendaal, Martin, et al. A World of Opportunities: Life-Style and Economic Behavior of 
Heroin Addicts in Amsterdam. State University of New York Press, 1995. !
Gray, James P. Why Our Drug Laws Have Failed and What We Can Do about It: a Judicial 
Indictment of the War on Drugs. Temple University Press, 2012. !
Gruber, Valerie A., et al. “A Randomized Trial of 6-Month Methadone Maintenance with 
Standard or Minimal Counseling versus 21-Day Methadone Detoxification.” Drug and 
Alcohol Dependence, vol. 94, no. 1-3, 1 Apr. 2008, pp. 199–206., doi:10.1016/
j.drugalcdep.2007.11.021. !
Gschwend, Patrick, et al. “Dosage Regimes in the Prescription of Heroin and Other Narcotics to 
Chronic Opioid Addicts in Switzerland: a Swiss National Cohort Study.” European 
Addiction Research, vol. 10, no. 1, 2003, pp. 41–48., doi:10.1159/000073725. !
Guttinger, Franziska, et al. “Evaluating Long-Term Effects of Heroin-Assisted Treatment: The 
Results of a 6-Year Follow-Up.” European Addiction Research, vol. 9, no. 2, 2003, pp. 
73–79., doi:10.1159/000068811. !
!78
Guy, Jerry P., et al. “ Vital Signs: Changes in Opioid Prescribing in the United States, 2006 - 
2015.” Morbidity and Mortality Weekly Report, CDC, 7 July 2017, www.cdc.gov/mmwr/
volumes/66/wr/pdfs/mm6626a4.pdf. !
Hampton, Ryan. “Purdue Pharma: You Can't Wash Away Your Part In The Opioid Crisis.” The 
Huffington Post, 15 Dec. 2017, www.huffingtonpost.com/entry/purdue-pharma-new-
york-times-ad_us_5a33f201e4b0e1b4472ae5cf. !
Heide, Chris. “Recovering Addict: Opioid Epidemic Will Be Endless If We Don't Do This.” 
CNN, 26 Oct. 2017, www.cnn.com/2017/10/26/opinions/opioid-crisis-needs-meaningful-
change-heide-opinion/index.html. !
Heller, Jacob L., ed. “Opiate and Opioid Withdrawal.” MedlinePlus Medical Encyclopedia, 20 
Apr. 2016, medlineplus.gov/ency/article/000949.htm. !
“Heroin Addiction: Get Help.” NHS Choices, NHS, 30 Apr. 2017, www.nhs.uk/Livewell/drugs/
Pages/Herointreatment.aspx. !
Kaplan, Sheila. “F.D.A. to Expand Medication-Assisted Therapy for Opioid Addicts.” The New 
York Times, 25 Feb. 2018, www.nytimes.com/2018/02/25/science/fda-medication-
assisted-therapy.html. !
Khan, Riaz, et al. “Understanding Swiss Drug Policy Change and the Introduction of Heroin 
Maintenance Treatment.” European Addiction Research, vol. 20, no. 4, 2014, pp. 200–
207., doi:10.1159/000357234. !
Labonville, Stephanie. “Opiate, Opioid, Narcotic - What's the Difference?” Anything But 
Generic, IWP, 29 Mar. 2017, info.iwpharmacy.com/opiate-opioid-narcotic-whats-the-
difference. !
Latour, Bruno. Science in Action: How to Follow Scientists and Engineers through Society. 
Harvard Univ. Press, 2015. !
Latour, Bruno. The Pasteurization of France. Harvard University Press, 1993. !
Law, John, and Michel Callon. “Engineering and Sociology in a Military Aircraft Project: A 
Network Analysis of Technological Change.” Social Problems, vol. 35, no. 3, 1988, pp. 
284–297., doi:10.1525/sp.1988.35.3.03a00060. !
Lintzeris, Nicholas, et al. “Methodology for the Randomised Injecting Opioid Treatment Trial 
(RIOTT): Evaluating Injectable Methadone and Injectable Heroin Treatment versus 
Optimised Oral Methadone Treatment in the UK.” Harm Reduction Journal, BioMed 
!79
Central, 27 Sept. 2006, harmreductionjournal.biomedcentral.com/articles/
10.1186/1477-7517-3-28. !
London, Mervyn. “History of Addiction: A UK Perspective.” American Journal on Addictions, 
vol. 14, no. 2, 2005, pp. 97–105., doi:10.1080/10550490590924719. !
Lopez, German. “Here's What Trump's Opioid Commission Wants Him to Do.” Vox, 1 Nov. 
2017, www.vox.com/policy-and-politics/2017/11/1/16589552/trump-opioid-commission-
final-report. !
Lopez, German. “There's a Highly Successful Treatment for Opioid Addiction. But Stigma Is 
Holding It Back.” Vox, 20 July 2017, www.vox.com/science-and-health/
2017/7/20/15937896/medication-assisted-treatment-methadone-buprenorphine-
naltrexone. !
Massing, Michael. The Fix. Simon & Schuster, 1998. !
Meier, Barry. “In Guilty Plea, OxyContin Maker to Pay $600 Million.” The New York Times, 10 
May 2007, www.nytimes.com/2007/05/10/business/11drug-web.html?mtrref=undefined. !
Musto, David F., et al. One Hundred Years of Heroin. Auburn House, 2002. !
National Institute on Drug Abuse. “Heroin.” Drug Facts, NIDA, Jan. 2018, www.drugabuse.gov/
publications/drugfacts/heroin. !
National Institute on Drug Abuse. “Overdose Death Rates.” NIDA, 15 Sept. 2017, 
www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. !
NIDA International Program, Methadone Research Web Guide, Part B-44. !
Platt, Jerome J., and Christina Labate. Heroin Addiction: Theory, Research, and Treatment. R.E. 
Krieger Pub. Co., 1986. !
“Preventing Overdose Deaths in Europe.” European Monitoring Center for Drugs and Drug 
Addiction, 6 June 2017, www.emcdda.europa.eu/topics/pods/preventing-overdose-
deaths_en. !
Ravitz, Jessica & Gena Somra. “What Two Current Heroin Addicts Want You to Know.” CNN, 
Cable News Network, 28 Oct. 2017, www.cnn.com/2017/10/26/health/heroin-addicts-
allie-johnny/index.html. !
!80
“Remarks by President Trump on Combatting the Opioid Crisis.” The White House, The United 
States Government, 19 Mar. 2018, www.whitehouse.gov/briefings-statements/remarks-
president-trump-combatting-opioid-crisis/. !
“Soldiers, Hippies and Richard Nixon – An American History of Methadone.” CRC Health 
Group, www.crchealth.com/addiction/heroin-addiction-treatment/heroin-detox/
history_methadone/. !
Solomon, Joshua. “NIH Study Validates Local Opioid Treatment Plan as a Nationwide Model.” 
The Recorder, 1 Jan. 2018, www.recorder.com/Local-opioid-expert-weighs-in-on-NIH-
study-14548077. !
St. Fleur, Nicholas. “Scientists, Feeling Under Siege, March Against Trump Policies.” The New 
York Times, 22 Apr. 2017, www.nytimes.com/2017/04/22/science/march-for-science.html. !
“Statistics on Drug Addiction.” American Addiction Centers, americanaddictioncenters.org/
rehab-guide/addiction-statistics/. !
Stephens, Richard C. The Street Addict Role: a Theory of Heroin Addiction. State University of 
New York Press, 1991. !
“Switzerland’s National Drugs Policy.” Swiss Federal Office of Public Health, 2006. !
“The Structure of the NHS in England.” NHS Choices, NHS, 13 Apr. 2014, www.nhs.uk/
NHSEngland/thenhs/about/Pages/nhsstructure.aspx. !
“Treatment Statistics.” Drug Facts, National Institute on Drug Abuse (NIDA). !
Trebach, Arnold S. The Heroin Solution. Unlimited Publishing, 2006. !
Uchtenhagen, Ambros. “Heroin-Assisted Treatment in Switzerland: a Case Study in Policy 
Change.” Addiction, vol. 105, no. 1, 2010, pp. 29–37., doi:10.1111/j.
1360-0443.2009.02741.x. !
United States, Congress, “Field Listing: Ethnic Groups,” World Factbook, CIA. www.cia.gov/
library/publications/the-world-factbook/fields/2075.html. !
Zoppo, Avalon R. “FBI Raids Methadone Clinic in Camden.” Philly.com, The Philadelphia 
Inquirer, 18 Apr. 2018, www.philly.com/philly/news/new_jersey/fbi-raid-methadone-
clinic-camden-20180418.html.
